Non-small Cell Lung Cancer
Conditions
Brief summary
This is a Phase II, randomized, multi-center, multinational, open-label, cross-over study in adult participants with PD-L1-positive NSCLC. Two populations will be included: participants with resected Stage II, IIIA, and selected IIIB (T3-N2) NSCLC who have completed adjuvant platinum-based chemotherapy without evidence of disease relapse/recurrence, and chemotherapy-naïve participants with Stage IV NSCLC. The study will evaluate participant- and healthcare professionals (HCP)-reported preference for atezolizumab subcutaneous (SC) compared with atezolizumab intravenous (IV).
Interventions
DRUGAtezolizumab
Atezolizumab will be administered on Day 1 of each 21-day cycle. Participants will receive atezolizumab according to their assigned route of administration (i.e., SC or IV) for the first three treatment cycles. At Cycle 4, participants will cross-over and receive atezolizumab administered according to the alternative route of administration for Cycles 4-6. This period of 3+3 cycles in both treatment arms constitutes the study Treatment Cross-over Period. After Cycle 6, participants will select how they would like atezolizumab to be administered (SC or IV) for the Treatment Continuation Period. The Treatment Continuation Period will continue until Cycle 16 for participants with early-stage NSCLC or until loss of clinical benefit, as determined by the investigator according to local standard of care, for patients with advanced NSCLC.
Sponsors
Hoffmann-La Roche
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
for All Participants: * ECOG performance status of 0 or 1 Inclusion Criteria for Participants with Early-stage NSCLC: * Participants must have a complete resection of a histologically or cytologically confirmed Stage II, IIIA, and selected IIIB (T3-N2) NSCLC * PD-L1 expression TC ≥ 1% or TPS ≥ 1% * Participants must have completed adjuvant chemotherapy at least 4 weeks and up to 12 weeks prior to randomization and must be adequately recovered from chemotherapy. For participants in the adjuvant setting, neoadjuvant chemotherapy or chemoradiotherapy is acceptable provided that participants also received adjuvant chemotherapy as per protocol's requirement. Inclusion Criteria for Participants with Stage IV NSCLC: * Histologically or cytologically confirmed, Stage IV non-squamous or squamous NSCLC * Life expectancy ≥ 18 weeks in the opinion of the investigator * PD-L1 expression TC ≥ 50% or TPS ≥ 50% or TC3 or IC3 * No prior systemic treatment for Stage IV non-squamous or squamous NSCLC * Participants who have received prior neo-adjuvant, adjuvant chemotherapy, radiotherapy, or chemoradiotherapy with curative intent for non-metastatic disease must have experienced a treatment-free interval of at least 6 months from randomization since the last chemotherapy, radiotherapy, or chemoradiotherapy cycle.
Exclusion criteria
for All Participants: * History of malignancy within 5 years prior to initiation of study treatment, with the exception of the cancer under investigation in this study and malignancies with a negligible risk of metastasis or death * Uncontrolled tumor-related pain * Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures * Participants known to have a sensitizing mutation in the EGFR gene or an ALK fusion oncogene * History of leptomeningeal disease * Uncontrolled or symptomatic hypercalcemia * Active or history of autoimmune disease or immune deficiency * History of idiopathic pulmonary fibrosis, organizing pneumonia), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan * Significant cardiovascular disease within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants Who Preferred Atezolizumab SC to Atezolizumab IV Assessed Using Patient Preference Questionnaire (PPQ) | Cycle 6 Day 1 (cycle length=21 days) | Participants preference was assessed based on the Question 1 of PPQ. Question 1 (All things considered, which route of administration did you prefer?) asks participants to report their preference for the route of administration (IV, SC, or no preference). A point estimate with associated 95% CI for the percentage of participants who preferred atezolizumab SC was calculated. Participants experiencing any of the following events: treatment withdrawal prior to eligibility for PPQ, or death without answering Question 1 of PPQ, or treatment not started; were excluded from the analysis set. Participants who answered Question 1 of the PPQ without having at least 2 consecutive administrations of treatment with each administration modality (SC and IV) were excluded from the analysis. Percentages have been rounded off. As planned, participant preference was summarized and presented by overall (all participants) and by randomized treatment sequence using FAS. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants Who Select Atezolizumab SC for Treatment Continuation Period | Cycle 6 Day 1 (Cycle length=21 days) | At Cycle 6, Day 1, participants were expected to select the route of study treatment administration (SC or IV) they would like to receive during the Treatment Continuation Period (starting at Cycle 7). Percentage of participants who chose SC administration have been reported here. Percentages have been rounded off. |
| Duration of Treatment Preparation According to Healthcare Professionals (HCPs) Response to Perception of Time, Assessed Using Question 1 of Healthcare Professional Questionnaires (HCPQs) - Drug Preparation Area | Day 1 of Cycles 1 to 6 (cycle length= 21 days) | The HCPQ- Drug Preparation Area Question 1 was completed by the HCPs within the pharmacy/drug preparation area where atezolizumab IV reconstitution or atezolizumab SC was prepared before the actual drug administration took place. The HCPQs were completed for every participant at each treatment cycle (Cycles 1-6, i.e., 3 cycles of atezolizumab IV followed by 3 cycles of atezolizumab SC or vice versa) of the treatment cross-over period. HCPs responded to the following parts of Question 1 that sought to evaluate the amount of time it took to prepare the IV infusion/SC injection of atezolizumab: How long (in minutes) did it take to prepare the treatment for use? |
| Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | Cycle 6 Day 1 (cycle length=21 days) | HCPs within pharmacy/drug preparation area responded to HCPQ-Drug Preparation Area Question 2 at Cycle 6 of Treatment Crossover Period for every participant: If all IV infusions are switched to SC, please indicate how strongly you agree/disagree with each of following statements: a=Staff will have increased availability for other tasks in pharmacy; b=Administrative procedures around atezolizumab SC will require less time; c=Atezolizumab SC formulations will provide more flexibility for staff in managing their workload; d=Due to ready-to-use atezolizumab SC formulations, potential dosing errors will be avoided; e=Due to ready-to-use atezolizumab SC formulations, there will be less drug wastage; f=Without having to reconstitute the drug, less storage space for atezolizumab SC related supplies will be required in pharmacy; g=Preparation procedures & associated time staff time commitment will be reduced, h=It will ease drug administration for participants with difficult venous access. |
| Percentage of HCPs by Their Response to Perception of Time/Resource Use for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 and 4 of HCPQ - Drug Preparation Area | Cycle 6 Day 1 (cycle length= 21 days) | HCPs who prepared study treatment within the pharmacy/drug preparation area responded at to the following HCPQ-Drug Preparation Area Questions 3 and 4, at Cycle 6 of the Treatment Crossover Period for every participant: Looking back over the Atezolizumab treatment sessions, please indicate based on your opinion which administration method: Question 3. Was quickest from start to end of preparation to finish of administration (excluding observation period)?; Question 4. Required less resource use for preparation and administration, for example nursing time, facility costs, equipment etc? The four available response options were: Atezolizumab IV, Atezolizumab SC, No Difference, and Missing. Percentages have been rounded off. |
| Duration of Treatment Administration Activities According to HCPs Response to Perception of Time, Assessed Using Question 1 of HCPQs - Treatment Room | Day 1 of Cycles 1 to 6 (cycle length=21 days) | The HCPQ-Treatment Room Question 1 was completed for every participant at each treatment cycle of the Treatment Crossover Period (Cycles 1-6,i.e., 3 cycles of atezolizumab IV followed by 3 cycles of atezolizumab SC/vice versa) by HCPs who administered treatment to the study participants. HCPs responded to following parts of Question 1 that sought to evaluate the amount of time it took to complete activities related to treatment administration: If new IV access was needed for this cycle of treatment, please indicate what type of IV access was provided (central venous catheter, peripherally inserted central catheter (PICC)/peripheral vein cannulation) & how long (in minutes) this took to set up (only for participants receiving IV treatment)? How long (in minutes) did it take to administer the treatment, i.e. total infusion duration? How long (in minutes) was the participant in the treatment room for in total? Durations with non-zero HCP responders have been reported here. |
| Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | Cycle 6 Day 1 (cycle length=21 days) | HCPs who administered treatment responded to Question 2: If all IV are switched to SC, please indicate how strongly you agree/disagree with each of following statements: a= Participants will be moved outside of infusion unit to receive SC injections (physician consultation room); b=Atezolizumab SC route will allow more flexible treatment scheduling; c=More participants will be treated in infusion unit; d=Waiting list for any IV treatment at infusion unit will be reduced; e=Staff resources will be re distributed to other departments of the hospital (less staffing required within infusion unit); f=There will still be sufficient interaction time between HCPs & participants (for participant education); g=Staff will spend more time for further professional education/development; h=Staff will dedicate more time to attending to administrative tasks for participants; i=Participants will spend less time in care unit; j=Administration by atezolizumab SC injection is preferred by participants. |
| Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Cycle 6 Day 1 (cycle length=21 days) | HCPs who administered study treatment responded at Cycle 6 of the Treatment Crossover Period to the following HCPQ-treatment room Questions 3 to 7: Looking back over the atezolizumab treatment sessions, please indicate based on your opinion which administration method: Question 3. Which method was most convenient for the participant? Question 4. Which method was best for optimizing participant care in your center? Question 5. Which method took the least time from start to finish of administration? Question 6. Which method required the least resource use for administration? Question 7. Which method was preferred by participants? The five available response options were: Atezolizumab SC, Atezolizumab IV, No Difference, Unsure and Missing. Percentages have been rounded off. |
| Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 8 of HCPQ - Treatment Room | Cycle 6 Day 1 (cycle length= 21 days) | HCPs who administered study treatment responded at Cycle 6 of the treatment Cross-over Period to the following HCPQ-treatment room Question 8: How frequently would you offer or recommend atezolizumab SC administration to your participants in the future? The four available response options were Always, Sometimes, Never and Missing. Percentages have been rounded off. |
| Change From Baseline Over Time in Physical Functioning Scale Score as Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC-QLQ-C30) | Baseline, Day 1 of Cycles 3, 6, 7, 10, 13, 16 and End of Treatment (up to approximately 2.2 years) | EORTC QLQ-C30 consists of 30 questions that assess five aspects of participant functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), global health status (GHS) and quality of life (QoL), and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) with a recall period of the previous week. Scale scores can be obtained for the multi-item scales. The functioning items are scored on a 4-point scale (1=Not at All to 4=Very Much). Scores are linearly transformed on a scale of 0 to 100, with a high score indicating better functioning. EORTC QLQ-C30 data was scored according to the EORTC scoring manual v3.0. In the event of incomplete data, if more than 50% of the constituent items were completed, a pro-rated score was computed. For subscales with less than 50% of the items completed, the subscale was considered as missing. |
| Change From Baseline Over Time in Role Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Baseline, Day 1 of Cycles 3, 6, 7, 10, 13, 16 and End of Treatment (up to approximately 2.2 years) | EORTC QLQ-C30 consists of 30 questions that assess five aspects of participant functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), GHS and QoL, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) with a recall period of the previous week. Scale scores can be obtained for the multi-item scales. The functioning items are scored on a 4-point scale (1=Not at All to 4=Very Much). Scores are linearly transformed on a scale of 0 to 100, with a high score indicating better functioning. EORTC QLQ-C30 data was scored according to the EORTC scoring manual v3.0. In the event of incomplete data, if more than 50% of the constituent items were completed, a pro-rated score was computed. For subscales with less than 50% of the items completed, the subscale was considered as missing. |
| Change From Baseline Over Time in Emotional Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Baseline, Day 1 of Cycles 3, 6, 7, 10, 13, 16 and End of Treatment (up to approximately 2.2 years) | EORTC QLQ-C30 consists of 30 questions that assess five aspects of participant functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), GHS and QoL, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) with a recall period of the previous week. Scale scores can be obtained for the multi-item scales. The functioning items are scored on a 4-point scale (1=Not at All to 4=Very Much). Scores are linearly transformed on a scale of 0 to 100, with a high score indicating better functioning. EORTC QLQ-C30 data was scored according to the EORTC scoring manual v3.0. In the event of incomplete data, if more than 50% of the constituent items were completed, a pro-rated score was computed. For subscales with less than 50% of the items completed, the subscale was considered as missing. |
| Change From Baseline Over Time in Cognitive Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Baseline, Day 1 of Cycles 3, 6, 7, 10, 13, 16 and End of Treatment (up to approximately 2.2 years) | EORTC QLQ-C30 consists of 30 questions that assess five aspects of participant functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), GHS and QoL, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) with a recall period of the previous week. Scale scores can be obtained for the multi-item scales. The functioning items are scored on a 4-point scale (1=Not at All to 4=Very Much). Scores are linearly transformed on a scale of 0 to 100, with a high score indicating better functioning. EORTC QLQ-C30 data was scored according to the EORTC scoring manual v3.0. In the event of incomplete data, if more than 50% of the constituent items were completed, a pro-rated score was computed. For subscales with less than 50% of the items completed, the subscale was considered as missing. |
| Change From Baseline Over Time in Social Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Baseline, Day 1 of Cycles 3, 6, 7, 10, 13, 16 and End of Treatment (up to approximately 2.2 years) | EORTC QLQ-C30 consists of 30 questions that assess five aspects of participant functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), GHS and QoL, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) with a recall period of the previous week. Scale scores can be obtained for the multi-item scales. The functioning items are scored on a 4-point scale (1=Not at All to 4=Very Much). Scores are linearly transformed on a scale of 0 to 100, with a high score indicating better functioning. EORTC QLQ-C30 data was scored according to the EORTC scoring manual v3.0. In the event of incomplete data, if more than 50% of the constituent items were completed, a pro-rated score was computed. For subscales with less than 50% of the items completed, the subscale was considered as missing. |
| Number of Participants by Their Level of Satisfaction With Atezolizumab SC and Atezolizumab IV Assessed Using Therapy Administration Satisfaction Questionnaire - Subcutaneous (TASQ-SC) and Intravenous (TASQ-IV) | Cycles 3 Day 1 and Cycle 6 Day 1 (cycle length=21 days) | TASQ is a 12-item, participant-reported questionnaire measuring the impact of each mode of treatment administration (TASQ-IV for IV treatment and TASQ-SC for SC treatment) on five domains: Physical Impact, Psychological Impact, Impact on Activities of Daily Living, Convenience, and Satisfaction. TASQ-IV/-SC was administered at treatment Cycles 3 and 6 according to the order of treatment received per arm during the Crossover Period. Participants satisfaction was assessed based on the Question 1 of TASQ-IV/SC which asks participants about their satisfaction with respect to route of administration (very satisfied, satisfied, neither satisfied nor dissatisfied, dissatisfied, participant did not answer the question). Question 1 - TASQ- IV (How satisfied or dissatisfied were you with the IV infusion?) and TASQ- SC (How satisfied or dissatisfied were you with the SC injection?) |
| Change From Baseline Over Time in Nausea and Vomiting Scale Score as Assessed by EORTC-QLQ-C30 | Baseline, Day 1 of Cycles 3, 6, 7, 10, 13, 16 and End of Treatment (up to approximately 2.2 years) | EORTC QLQ-C30 consists of 30 questions that assess five aspects of participant functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), GHS and QoL, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) with a recall period of the previous week. Scale scores can be obtained for the multi-item scales. The symptom items are scored on a 4-point scale (1=Not at All to 4=Very Much). Scores are linearly transformed on a scale of 0 to 100, with a high score indicating worst symptoms. EORTC QLQ-C30 data was scored according to the EORTC scoring manual v3.0. In the event of incomplete data, if more than 50% of the constituent items were completed, a pro-rated score was computed. For subscales with less than 50% of the items completed, the subscale was considered as missing. |
| Change From Baseline Over Time in Pain Scale Score as Assessed by EORTC-QLQ-C30 | Baseline, Day 1 of Cycles 3, 6, 7, 10, 13, 16 and End of Treatment (up to approximately 2.2 years) | EORTC QLQ-C30 consists of 30 questions that assess five aspects of participant functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), GHS and QoL, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) with a recall period of the previous week. Scale scores can be obtained for the multi-item scales. The symptom items are scored on a 4-point scale (1=Not at All to 4=Very Much). Scores are linearly transformed on a scale of 0 to 100, with a high score indicating worst symptoms. EORTC QLQ-C30 data was scored according to the EORTC scoring manual v3.0. In the event of incomplete data, if more than 50% of the constituent items were completed, a pro-rated score was computed. For subscales with less than 50% of the items completed, the subscale was considered as missing. |
| Change From Baseline Over Time in Dyspnoea Scale Score as Assessed by EORTC-QLQ-C30 | Baseline, Day 1 of Cycles 3, 6, 7, 10, 13, 16 and End of Treatment (up to approximately 2.2 years) | EORTC QLQ-C30 consists of 30 questions that assess five aspects of participant functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), GHS and QoL, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) with a recall period of the previous week. Scale scores can be obtained for the multi-item scales. The dyspnoea scale items are scored on a 4-point scale (1=Not at All to 4=Very Much). Scores are linearly transformed on a scale of 0 to 100, with a high score the scale indicating worst symptoms. EORTC QLQ-C30 data was scored according to the EORTC scoring manual v3.0. In the event of incomplete data, if more than 50% of the constituent items were completed, a pro-rated score was computed. For subscales with less than 50% of the items completed, the subscale was considered as missing. |
| Change From Baseline Over Time in Insomnia Scale Score as Assessed by EORTC-QLQ-C30 | Baseline, Day 1 of Cycles 3, 6, 7, 10, 13, 16 and End of Treatment (up to approximately 2.2 years) | EORTC QLQ-C30 consists of 30 questions that assess five aspects of participant functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), GHS and QoL, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) with a recall period of the previous week. Scale scores can be obtained for the multi-item scales. The insomnia scale items are scored on a 4-point scale (1=Not at All to 4=Very Much). Scores are linearly transformed on a scale of 0 to 100, with a high score on the scale indicating worst symptoms. EORTC QLQ-C30 data was scored according to the EORTC scoring manual v3.0. In the event of incomplete data, if more than 50% of the constituent items were completed, a pro-rated score was computed. For subscales with less than 50% of the items completed, the subscale was considered as missing. |
| Change From Baseline Over Time in Appetite Loss Scale Score as Assessed by EORTC-QLQ-C30 | Baseline, Day 1 of Cycles 3, 6, 7, 10, 13, 16 and End of Treatment (up to approximately 2.2 years) | EORTC QLQ-C30 consists of 30 questions that assess five aspects of participant functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), GHS and QoL, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) with a recall period of the previous week. Scale scores can be obtained for the multi-item scales. The appetite loss scale items are scored on a 4-point scale (1=Not at All to 4=Very Much). Scores are linearly transformed on a scale of 0 to 100, with a high score on the scale indicating worst symptoms. EORTC QLQ-C30 data was scored according to the EORTC scoring manual v3.0. In the event of incomplete data, if more than 50% of the constituent items were completed, a pro-rated score was computed. For subscales with less than 50% of the items completed, the subscale was considered as missing. |
| Change From Baseline Over Time in Constipation Scale Score as Assessed by EORTC-QLQ-C30 | Baseline, Day 1 of Cycles 3, 6, 7, 10, 13, 16 and End of Treatment (up to approximately 2.2 years) | EORTC QLQ-C30 consists of 30 questions that assess five aspects of participant functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), GHS and QoL, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) with a recall period of the previous week. Scale scores can be obtained for the multi-item scales. The constipation scale items are scored on a 4-point scale (1=Not at All to 4=Very Much). Scores are linearly transformed on a scale of 0 to 100, with a high score on the scale indicating worst symptoms. EORTC QLQ-C30 data was scored according to the EORTC scoring manual v3.0. In the event of incomplete data, if more than 50% of the constituent items were completed, a pro-rated score was computed. For subscales with less than 50% of the items completed, the subscale was considered as missing. |
| Change From Baseline Over Time in Diarrhoea Scale Score as Assessed by EORTC-QLQ-C30 | Baseline, Day 1 of Cycles 3, 6, 7, 10, 13, 16 and End of Treatment (up to approximately 2.2 years) | EORTC QLQ-C30 consists of 30 questions that assess five aspects of participant functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), GHS and QoL, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) with a recall period of the previous week. Scale scores can be obtained for the multi-item scales. The diarrhoea scale items are scored on a 4-point scale (1=Not at All to 4=Very Much). Scores are linearly transformed on a scale of 0 to 100, with a high score on the scale indicating worst symptoms. EORTC QLQ-C30 data was scored according to the EORTC scoring manual v3.0. In the event of incomplete data, if more than 50% of the constituent items were completed, a pro-rated score was computed. For subscales with less than 50% of the items completed, the subscale was considered as missing. |
| Change From Baseline Over Time in Financial Difficulties Scale Score as Assessed by EORTC-QLQ-C30 | Baseline, Day 1 of Cycles 3, 6, 7, 10, 13, 16 and End of Treatment (up to approximately 2.2 years) | EORTC QLQ-C30 consists of 30 questions that assess five aspects of participant functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), GHS and QoL, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) with a recall period of the previous week. Scale scores can be obtained for the multi-item scales. The financial difficulties scale items are scored on a 4-point scale (1=Not at All to 4=Very Much). Scores are linearly transformed on a scale of 0 to 100, with a high score on the scale indicating worst functioning. EORTC QLQ-C30 data was scored according to the EORTC scoring manual v3.0. In the event of incomplete data, if more than 50% of the constituent items were completed, a pro-rated score was computed. For subscales with less than 50% of the items completed, the subscale was considered as missing. |
| Change From Baseline Over Time in Health-related Quality of Life (HRQoL) Score as Assessed by GHS/QoL Scale of the EORTC-QLQ-C30 | Baseline, Day 1 of Cycles 3, 6, 7, 10, 13, 16 and End of Treatment (up to approximately 2.2 years) | EORTC QLQ-C30 consists of 30 questions that assess participant functioning (physical, emotional, role, cognitive, and social), symptom scales (fatigue, nausea and vomiting, pain), global health/ QoL, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Change in HRQoL was assessed using participant responses to questions regarding Global Health Status (Q29: GHS; How would you rate your overall health during the past week?) and QoL (Q30: QoL; How would you rate your overall quality of life during the past week?) and were scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized. Scores range from 0-100. A higher score indicates a better outcome. |
| Percentage of Participants With Ongoing Clinical Benefit | Up to Cycle 16 (cycle length= 21 days) | Participants were assessed for clinical benefit at every tumour assessment visit, which was conducted as per the local standard of care. Percentages have been rounded off. |
| Percentage of Participants With Adverse Events (AEs) | Up to 90 days after the final dose of study drug (Up to 2.4 years) | An AE is untoward medical occurrence in a participant administered a pharmaceutical product and regardless of causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom/disease temporally associated with use of investigational product, whether or not considered related to the investigational product. Percentages have been rounded off. |
| Percentage of Participants With AEs During Treatment Cross-over Period | From Cycle 1 Day 1 up to Cycle 3 Day 21; From Cycle 4 Day 1 up to Cycle 6 Day 21 (cycle length=21 days) | An AE is untoward medical occurrence in participant administered a pharmaceutical product and regardless of causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom/disease temporally associated with use of investigational product, whether or not considered related to investigational product. The safety of switching from atezolizumab SC to atezolizumab IV and from atezolizumab IV to atezolizumab SC is being assessed in this outcome measure. Percentages have been rounded off. |
| Change From Baseline Over Time in Fatigue Scale Score as Assessed by EORTC-QLQ-C30 | Baseline, Day 1 of Cycles 3, 6, 7, 10, 13, 16 and End of Treatment (up to approximately 2.2 years) | EORTC QLQ-C30 consists of 30 questions that assess five aspects of participant functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), GHS and QoL, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) with a recall period of the previous week. Scale scores can be obtained for the multi-item scales. The symptom items are scored on a 4-point scale (1=Not at All to 4=Very Much). Scores are linearly transformed on a scale of 0 to 100, with a high score indicating worst symptoms. EORTC QLQ-C30 data was scored according to the EORTC scoring manual v3.0. In the event of incomplete data, if more than 50% of the constituent items were completed, a pro-rated score was computed. For subscales with less than 50% of the items completed, the subscale was considered as missing. |
Countries
Argentina, Brazil, Canada, Chile, Costa Rica, Finland, Italy, Latvia, Poland, South Korea, Spain, United States
Participant flow
Recruitment details
Participants took part in the study across 37 investigative sites in 12 countries (Spain, Brazil, Finland, Italy, United States, Argentina, Canada, Republic of Korea, Costa Rica, Latvia, Poland, and Chile) from 04 April 2022 to 25 October 2024.
Pre-assignment details
A total of 179 participants with non-small cell lung cancer (NSCLC) were randomized in 1:1 ratio to Arm A (atezolizumab IV followed by atezolizumab SC) or Arm B (atezolizumab SC followed by atezolizumab IV). The study consists of two periods: Treatment Crossover Period, and Treatment Continuation Period.
Participants by arm
| Arm | Count |
|---|---|
| Crossover Atezolizumab IV/SC Participants were administered atezolizumab, IV infusion, 1200 mg, Q3W for 3 cycles followed by atezolizumab, SC injections, 1875 mg, Q3W, for the next 3 cycles (cycle length=21 days) in the Treatment Crossover Period. | 89 |
| Crossover Atezolizumab SC/IV Participants were administered atezolizumab, SC injections, 1875 mg, Q3W for 3 cycles followed by atezolizumab, IV, 1200 mg, Q3W, for the next 3 cycles (cycle length=21 days) in the Treatment Crossover Period. | 90 |
| Total | 179 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Treatment Continuation Period | Adverse Event | 0 | 0 | 3 | 6 |
| Treatment Continuation Period | Death | 0 | 0 | 1 | 3 |
| Treatment Continuation Period | Disease Relapse | 0 | 0 | 1 | 0 |
| Treatment Continuation Period | Lack of Efficacy | 0 | 0 | 0 | 1 |
| Treatment Continuation Period | Physician Decision | 0 | 0 | 0 | 4 |
| Treatment Continuation Period | Progressive Disease | 0 | 0 | 6 | 20 |
| Treatment Continuation Period | Study Ended by Sponsor | 0 | 0 | 4 | 15 |
| Treatment Continuation Period | Symptomatic Deterioration | 0 | 0 | 0 | 2 |
| Treatment Continuation Period | Withdrawal by Subject | 0 | 0 | 0 | 6 |
| Treatment Crossover Period | Adverse Event | 9 | 6 | 0 | 0 |
| Treatment Crossover Period | Death | 5 | 5 | 0 | 0 |
| Treatment Crossover Period | Disease Relapse | 1 | 0 | 0 | 0 |
| Treatment Crossover Period | Physician Decision | 0 | 1 | 0 | 0 |
| Treatment Crossover Period | Progressive Disease | 14 | 10 | 0 | 0 |
| Treatment Crossover Period | Protocol Violation | 0 | 2 | 0 | 0 |
| Treatment Crossover Period | Reason not Specified | 1 | 1 | 0 | 0 |
| Treatment Crossover Period | Symptomatic Deterioration | 0 | 1 | 0 | 0 |
| Treatment Crossover Period | Withdrawal by Subject | 4 | 4 | 0 | 0 |
Baseline characteristics
| Characteristic | Crossover Atezolizumab SC/IV | Total | Crossover Atezolizumab IV/SC |
|---|---|---|---|
| Age, Continuous | 67.7 years STANDARD_DEVIATION 9.4 | 67.0 years STANDARD_DEVIATION 9.3 | 66.3 years STANDARD_DEVIATION 9.2 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 18 Participants | 38 Participants | 20 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 62 Participants | 117 Participants | 55 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 10 Participants | 24 Participants | 14 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 2 Participants | 3 Participants | 1 Participants |
| Race (NIH/OMB) Asian | 8 Participants | 13 Participants | 5 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 6 Participants | 13 Participants | 7 Participants |
| Race (NIH/OMB) White | 74 Participants | 149 Participants | 75 Participants |
| Sex: Female, Male Female | 32 Participants | 60 Participants | 28 Participants |
| Sex: Female, Male Male | 58 Participants | 119 Participants | 61 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk |
|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 16 / 160 | 21 / 155 | 5 / 26 | 12 / 89 | 54 / 175 |
| other Total, other adverse events | 60 / 160 | 52 / 155 | 16 / 26 | 44 / 89 | 172 / 175 |
| serious Total, serious adverse events | 15 / 160 | 13 / 155 | 6 / 26 | 12 / 89 | 45 / 175 |
Outcome results
Primary
Percentage of Participants Who Preferred Atezolizumab SC to Atezolizumab IV Assessed Using Patient Preference Questionnaire (PPQ)
Participants preference was assessed based on the Question 1 of PPQ. Question 1 (All things considered, which route of administration did you prefer?) asks participants to report their preference for the route of administration (IV, SC, or no preference). A point estimate with associated 95% CI for the percentage of participants who preferred atezolizumab SC was calculated. Participants experiencing any of the following events: treatment withdrawal prior to eligibility for PPQ, or death without answering Question 1 of PPQ, or treatment not started; were excluded from the analysis set. Participants who answered Question 1 of the PPQ without having at least 2 consecutive administrations of treatment with each administration modality (SC and IV) were excluded from the analysis. Percentages have been rounded off. As planned, participant preference was summarized and presented by overall (all participants) and by randomized treatment sequence using FAS.
Time frame: Cycle 6 Day 1 (cycle length=21 days)
Population: FAS included all randomized participants. Overall number analyzed is the number of participants who answered Question 1 of PPQ.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Crossover Atezolizumab IV/SC | Percentage of Participants Who Preferred Atezolizumab SC to Atezolizumab IV Assessed Using Patient Preference Questionnaire (PPQ) | 71.67 percentage of participants |
| Crossover Atezolizumab SC/IV | Percentage of Participants Who Preferred Atezolizumab SC to Atezolizumab IV Assessed Using Patient Preference Questionnaire (PPQ) | 69.84 percentage of participants |
| All Participants | Percentage of Participants Who Preferred Atezolizumab SC to Atezolizumab IV Assessed Using Patient Preference Questionnaire (PPQ) | 70.73 percentage of participants |
Secondary
Change From Baseline Over Time in Appetite Loss Scale Score as Assessed by EORTC-QLQ-C30
EORTC QLQ-C30 consists of 30 questions that assess five aspects of participant functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), GHS and QoL, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) with a recall period of the previous week. Scale scores can be obtained for the multi-item scales. The appetite loss scale items are scored on a 4-point scale (1=Not at All to 4=Very Much). Scores are linearly transformed on a scale of 0 to 100, with a high score on the scale indicating worst symptoms. EORTC QLQ-C30 data was scored according to the EORTC scoring manual v3.0. In the event of incomplete data, if more than 50% of the constituent items were completed, a pro-rated score was computed. For subscales with less than 50% of the items completed, the subscale was considered as missing.
Time frame: Baseline, Day 1 of Cycles 3, 6, 7, 10, 13, 16 and End of Treatment (up to approximately 2.2 years)
Population: FAS included all randomized participants. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at specified timepoint.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Appetite Loss Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | -6.06 score on a scale | Standard Deviation 25.03 |
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Appetite Loss Scale Score as Assessed by EORTC-QLQ-C30 | Baseline | 16.67 score on a scale | Standard Deviation 28.14 |
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Appetite Loss Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 3 Day 1 | 2.31 score on a scale | Standard Deviation 32.3 |
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Appetite Loss Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 6 Day 1 | 2.87 score on a scale | Standard Deviation 30.13 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Appetite Loss Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 3 Day 1 | 2.22 score on a scale | Standard Deviation 23.46 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Appetite Loss Scale Score as Assessed by EORTC-QLQ-C30 | Baseline | 21.96 score on a scale | Standard Deviation 28.43 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Appetite Loss Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 6 Day 1 | -2.19 score on a scale | Standard Deviation 26.44 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Appetite Loss Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | 3.33 score on a scale | Standard Deviation 36.68 |
| All Participants | Change From Baseline Over Time in Appetite Loss Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 16 Day 1 | 0.00 score on a scale | Standard Deviation 13.07 |
| All Participants | Change From Baseline Over Time in Appetite Loss Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | 0.00 score on a scale | Standard Deviation 31.08 |
| All Participants | Change From Baseline Over Time in Appetite Loss Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 7 Day 1 | 4.17 score on a scale | Standard Deviation 30 |
| All Participants | Change From Baseline Over Time in Appetite Loss Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 10 Day 1 | 6.06 score on a scale | Standard Deviation 35.09 |
| All Participants | Change From Baseline Over Time in Appetite Loss Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 13 Day 1 | -1.96 score on a scale | Standard Deviation 18.52 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Appetite Loss Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | 2.63 score on a scale | Standard Deviation 25.97 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Appetite Loss Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 7 Day 1 | -3.03 score on a scale | Standard Deviation 27.14 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Appetite Loss Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 10 Day 1 | -2.03 score on a scale | Standard Deviation 25.31 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Appetite Loss Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 13 Day 1 | -0.46 score on a scale | Standard Deviation 26.35 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Appetite Loss Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 16 Day 1 | 0.00 score on a scale | Standard Deviation 25.29 |
Secondary
Change From Baseline Over Time in Cognitive Functioning Scale Score as Assessed by EORTC-QLQ-C30
EORTC QLQ-C30 consists of 30 questions that assess five aspects of participant functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), GHS and QoL, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) with a recall period of the previous week. Scale scores can be obtained for the multi-item scales. The functioning items are scored on a 4-point scale (1=Not at All to 4=Very Much). Scores are linearly transformed on a scale of 0 to 100, with a high score indicating better functioning. EORTC QLQ-C30 data was scored according to the EORTC scoring manual v3.0. In the event of incomplete data, if more than 50% of the constituent items were completed, a pro-rated score was computed. For subscales with less than 50% of the items completed, the subscale was considered as missing.
Time frame: Baseline, Day 1 of Cycles 3, 6, 7, 10, 13, 16 and End of Treatment (up to approximately 2.2 years)
Population: FAS included all randomized participants. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at specified timepoint.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Cognitive Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | -6.94 score on a scale | Standard Deviation 25.08 |
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Cognitive Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 3 Day 1 | 2.31 score on a scale | Standard Deviation 17.31 |
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Cognitive Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Baseline | 87.31 score on a scale | Standard Deviation 21.74 |
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Cognitive Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 6 Day 1 | -5.75 score on a scale | Standard Deviation 18.87 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Cognitive Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Baseline | 85.69 score on a scale | Standard Deviation 19.78 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Cognitive Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 6 Day 1 | -1.09 score on a scale | Standard Deviation 20.15 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Cognitive Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | 3.33 score on a scale | Standard Deviation 17.21 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Cognitive Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 3 Day 1 | -5.56 score on a scale | Standard Deviation 19.05 |
| All Participants | Change From Baseline Over Time in Cognitive Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 16 Day 1 | -7.14 score on a scale | Standard Deviation 12.6 |
| All Participants | Change From Baseline Over Time in Cognitive Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | -5.56 score on a scale | Standard Deviation 23.4 |
| All Participants | Change From Baseline Over Time in Cognitive Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 7 Day 1 | -4.17 score on a scale | Standard Deviation 13.23 |
| All Participants | Change From Baseline Over Time in Cognitive Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 10 Day 1 | -5.30 score on a scale | Standard Deviation 11.94 |
| All Participants | Change From Baseline Over Time in Cognitive Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 13 Day 1 | -11.76 score on a scale | Standard Deviation 21.86 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Cognitive Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | -7.36 score on a scale | Standard Deviation 22.7 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Cognitive Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 7 Day 1 | -2.16 score on a scale | Standard Deviation 19.37 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Cognitive Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 10 Day 1 | -0.41 score on a scale | Standard Deviation 17.76 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Cognitive Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 13 Day 1 | -1.14 score on a scale | Standard Deviation 21.21 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Cognitive Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 16 Day 1 | -2.99 score on a scale | Standard Deviation 21.11 |
Secondary
Change From Baseline Over Time in Constipation Scale Score as Assessed by EORTC-QLQ-C30
EORTC QLQ-C30 consists of 30 questions that assess five aspects of participant functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), GHS and QoL, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) with a recall period of the previous week. Scale scores can be obtained for the multi-item scales. The constipation scale items are scored on a 4-point scale (1=Not at All to 4=Very Much). Scores are linearly transformed on a scale of 0 to 100, with a high score on the scale indicating worst symptoms. EORTC QLQ-C30 data was scored according to the EORTC scoring manual v3.0. In the event of incomplete data, if more than 50% of the constituent items were completed, a pro-rated score was computed. For subscales with less than 50% of the items completed, the subscale was considered as missing.
Time frame: Baseline, Day 1 of Cycles 3, 6, 7, 10, 13, 16 and End of Treatment (up to approximately 2.2 years)
Population: FAS included all randomized participants. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at specified timepoint.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Constipation Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | -12.12 score on a scale | Standard Deviation 45.39 |
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Constipation Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 3 Day 1 | 0.00 score on a scale | Standard Deviation 29.07 |
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Constipation Scale Score as Assessed by EORTC-QLQ-C30 | Baseline | 19.32 score on a scale | Standard Deviation 30.63 |
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Constipation Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 6 Day 1 | -4.60 score on a scale | Standard Deviation 28.92 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Constipation Scale Score as Assessed by EORTC-QLQ-C30 | Baseline | 21.96 score on a scale | Standard Deviation 33.55 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Constipation Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 6 Day 1 | -3.28 score on a scale | Standard Deviation 30.25 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Constipation Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | 16.67 score on a scale | Standard Deviation 39.28 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Constipation Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 3 Day 1 | -2.67 score on a scale | Standard Deviation 32.77 |
| All Participants | Change From Baseline Over Time in Constipation Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 16 Day 1 | -4.76 score on a scale | Standard Deviation 17.82 |
| All Participants | Change From Baseline Over Time in Constipation Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | 1.39 score on a scale | Standard Deviation 23.01 |
| All Participants | Change From Baseline Over Time in Constipation Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 7 Day 1 | -4.17 score on a scale | Standard Deviation 20.41 |
| All Participants | Change From Baseline Over Time in Constipation Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 10 Day 1 | -3.03 score on a scale | Standard Deviation 25.01 |
| All Participants | Change From Baseline Over Time in Constipation Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 13 Day 1 | -1.96 score on a scale | Standard Deviation 21.96 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Constipation Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | -3.46 score on a scale | Standard Deviation 35.29 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Constipation Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 7 Day 1 | -9.52 score on a scale | Standard Deviation 34.98 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Constipation Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 10 Day 1 | -6.10 score on a scale | Standard Deviation 30.6 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Constipation Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 13 Day 1 | -4.11 score on a scale | Standard Deviation 29.37 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Constipation Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 16 Day 1 | -1.00 score on a scale | Standard Deviation 32.29 |
Secondary
Change From Baseline Over Time in Diarrhoea Scale Score as Assessed by EORTC-QLQ-C30
EORTC QLQ-C30 consists of 30 questions that assess five aspects of participant functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), GHS and QoL, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) with a recall period of the previous week. Scale scores can be obtained for the multi-item scales. The diarrhoea scale items are scored on a 4-point scale (1=Not at All to 4=Very Much). Scores are linearly transformed on a scale of 0 to 100, with a high score on the scale indicating worst symptoms. EORTC QLQ-C30 data was scored according to the EORTC scoring manual v3.0. In the event of incomplete data, if more than 50% of the constituent items were completed, a pro-rated score was computed. For subscales with less than 50% of the items completed, the subscale was considered as missing.
Time frame: Baseline, Day 1 of Cycles 3, 6, 7, 10, 13, 16 and End of Treatment (up to approximately 2.2 years)
Population: FAS included all randomized participants. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at specified timepoint.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Diarrhoea Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | -5.56 score on a scale | Standard Deviation 19.25 |
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Diarrhoea Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 3 Day 1 | 0.93 score on a scale | Standard Deviation 18.53 |
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Diarrhoea Scale Score as Assessed by EORTC-QLQ-C30 | Baseline | 5.68 score on a scale | Standard Deviation 15.35 |
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Diarrhoea Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 6 Day 1 | -2.30 score on a scale | Standard Deviation 17.51 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Diarrhoea Scale Score as Assessed by EORTC-QLQ-C30 | Baseline | 7.06 score on a scale | Standard Deviation 15.51 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Diarrhoea Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 6 Day 1 | 3.28 score on a scale | Standard Deviation 21.69 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Diarrhoea Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | -13.33 score on a scale | Standard Deviation 23.31 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Diarrhoea Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 3 Day 1 | 2.22 score on a scale | Standard Deviation 18.45 |
| All Participants | Change From Baseline Over Time in Diarrhoea Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 16 Day 1 | 9.52 score on a scale | Standard Deviation 30.46 |
| All Participants | Change From Baseline Over Time in Diarrhoea Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | 5.56 score on a scale | Standard Deviation 27.22 |
| All Participants | Change From Baseline Over Time in Diarrhoea Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 7 Day 1 | 2.78 score on a scale | Standard Deviation 16.79 |
| All Participants | Change From Baseline Over Time in Diarrhoea Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 10 Day 1 | 4.55 score on a scale | Standard Deviation 18.67 |
| All Participants | Change From Baseline Over Time in Diarrhoea Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 13 Day 1 | 9.80 score on a scale | Standard Deviation 34.89 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Diarrhoea Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | -0.43 score on a scale | Standard Deviation 20.59 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Diarrhoea Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 7 Day 1 | -1.30 score on a scale | Standard Deviation 19.82 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Diarrhoea Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 10 Day 1 | 2.03 score on a scale | Standard Deviation 19.14 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Diarrhoea Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 13 Day 1 | -1.83 score on a scale | Standard Deviation 16.56 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Diarrhoea Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 16 Day 1 | 0.50 score on a scale | Standard Deviation 22.09 |
Secondary
Change From Baseline Over Time in Dyspnoea Scale Score as Assessed by EORTC-QLQ-C30
EORTC QLQ-C30 consists of 30 questions that assess five aspects of participant functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), GHS and QoL, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) with a recall period of the previous week. Scale scores can be obtained for the multi-item scales. The dyspnoea scale items are scored on a 4-point scale (1=Not at All to 4=Very Much). Scores are linearly transformed on a scale of 0 to 100, with a high score the scale indicating worst symptoms. EORTC QLQ-C30 data was scored according to the EORTC scoring manual v3.0. In the event of incomplete data, if more than 50% of the constituent items were completed, a pro-rated score was computed. For subscales with less than 50% of the items completed, the subscale was considered as missing.
Time frame: Baseline, Day 1 of Cycles 3, 6, 7, 10, 13, 16 and End of Treatment (up to approximately 2.2 years)
Population: FAS included all randomized participants. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at specified timepoint.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Dyspnoea Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | 8.33 score on a scale | Standard Deviation 15.08 |
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Dyspnoea Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 3 Day 1 | 5.09 score on a scale | Standard Deviation 26.63 |
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Dyspnoea Scale Score as Assessed by EORTC-QLQ-C30 | Baseline | 25.38 score on a scale | Standard Deviation 26.26 |
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Dyspnoea Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 6 Day 1 | -0.57 score on a scale | Standard Deviation 22.07 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Dyspnoea Scale Score as Assessed by EORTC-QLQ-C30 | Baseline | 30.59 score on a scale | Standard Deviation 30.52 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Dyspnoea Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 6 Day 1 | -2.73 score on a scale | Standard Deviation 31.8 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Dyspnoea Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | 16.67 score on a scale | Standard Deviation 28.33 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Dyspnoea Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 3 Day 1 | 0.89 score on a scale | Standard Deviation 26.83 |
| All Participants | Change From Baseline Over Time in Dyspnoea Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 16 Day 1 | 0.00 score on a scale | Standard Deviation 29.24 |
| All Participants | Change From Baseline Over Time in Dyspnoea Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | 4.17 score on a scale | Standard Deviation 31.57 |
| All Participants | Change From Baseline Over Time in Dyspnoea Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 7 Day 1 | 4.17 score on a scale | Standard Deviation 31.57 |
| All Participants | Change From Baseline Over Time in Dyspnoea Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 10 Day 1 | 3.03 score on a scale | Standard Deviation 25.01 |
| All Participants | Change From Baseline Over Time in Dyspnoea Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 13 Day 1 | 0.00 score on a scale | Standard Deviation 28.87 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Dyspnoea Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | 2.60 score on a scale | Standard Deviation 26.36 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Dyspnoea Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 7 Day 1 | -3.03 score on a scale | Standard Deviation 27.14 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Dyspnoea Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 10 Day 1 | -5.28 score on a scale | Standard Deviation 25.37 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Dyspnoea Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 13 Day 1 | 0.00 score on a scale | Standard Deviation 24.22 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Dyspnoea Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 16 Day 1 | -4.48 score on a scale | Standard Deviation 26.52 |
Secondary
Change From Baseline Over Time in Emotional Functioning Scale Score as Assessed by EORTC-QLQ-C30
EORTC QLQ-C30 consists of 30 questions that assess five aspects of participant functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), GHS and QoL, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) with a recall period of the previous week. Scale scores can be obtained for the multi-item scales. The functioning items are scored on a 4-point scale (1=Not at All to 4=Very Much). Scores are linearly transformed on a scale of 0 to 100, with a high score indicating better functioning. EORTC QLQ-C30 data was scored according to the EORTC scoring manual v3.0. In the event of incomplete data, if more than 50% of the constituent items were completed, a pro-rated score was computed. For subscales with less than 50% of the items completed, the subscale was considered as missing.
Time frame: Baseline, Day 1 of Cycles 3, 6, 7, 10, 13, 16 and End of Treatment (up to approximately 2.2 years)
Population: FAS included all randomized participants. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at specified timepoint.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Emotional Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Baseline | 79.48 score on a scale | Standard Deviation 22.43 |
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Emotional Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 3 Day 1 | 2.62 score on a scale | Standard Deviation 20.52 |
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Emotional Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 6 Day 1 | 0.77 score on a scale | Standard Deviation 17.68 |
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Emotional Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | -6.71 score on a scale | Standard Deviation 16.98 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Emotional Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | -6.67 score on a scale | Standard Deviation 21.08 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Emotional Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Baseline | 75.98 score on a scale | Standard Deviation 23.44 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Emotional Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 6 Day 1 | 4.10 score on a scale | Standard Deviation 23.3 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Emotional Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 3 Day 1 | 0.89 score on a scale | Standard Deviation 16.47 |
| All Participants | Change From Baseline Over Time in Emotional Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 16 Day 1 | -2.98 score on a scale | Standard Deviation 23.02 |
| All Participants | Change From Baseline Over Time in Emotional Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | -8.33 score on a scale | Standard Deviation 28.45 |
| All Participants | Change From Baseline Over Time in Emotional Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 7 Day 1 | -3.47 score on a scale | Standard Deviation 22.64 |
| All Participants | Change From Baseline Over Time in Emotional Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 10 Day 1 | -3.03 score on a scale | Standard Deviation 26.92 |
| All Participants | Change From Baseline Over Time in Emotional Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 13 Day 1 | 0.98 score on a scale | Standard Deviation 22.61 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Emotional Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | -5.05 score on a scale | Standard Deviation 18.16 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Emotional Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 7 Day 1 | 2.56 score on a scale | Standard Deviation 15.84 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Emotional Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 10 Day 1 | 4.37 score on a scale | Standard Deviation 16.91 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Emotional Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 13 Day 1 | 3.46 score on a scale | Standard Deviation 19 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Emotional Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 16 Day 1 | 0.37 score on a scale | Standard Deviation 17.49 |
Secondary
Change From Baseline Over Time in Fatigue Scale Score as Assessed by EORTC-QLQ-C30
EORTC QLQ-C30 consists of 30 questions that assess five aspects of participant functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), GHS and QoL, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) with a recall period of the previous week. Scale scores can be obtained for the multi-item scales. The symptom items are scored on a 4-point scale (1=Not at All to 4=Very Much). Scores are linearly transformed on a scale of 0 to 100, with a high score indicating worst symptoms. EORTC QLQ-C30 data was scored according to the EORTC scoring manual v3.0. In the event of incomplete data, if more than 50% of the constituent items were completed, a pro-rated score was computed. For subscales with less than 50% of the items completed, the subscale was considered as missing.
Time frame: Baseline, Day 1 of Cycles 3, 6, 7, 10, 13, 16 and End of Treatment (up to approximately 2.2 years)
Population: FAS included all randomized participants. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at specified timepoint.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Fatigue Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | 6.48 score on a scale | Standard Deviation 24.37 |
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Fatigue Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 3 Day 1 | 0.15 score on a scale | Standard Deviation 26.67 |
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Fatigue Scale Score as Assessed by EORTC-QLQ-C30 | Baseline | 30.81 score on a scale | Standard Deviation 25.81 |
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Fatigue Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 6 Day 1 | 4.41 score on a scale | Standard Deviation 25.06 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Fatigue Scale Score as Assessed by EORTC-QLQ-C30 | Baseline | 36.08 score on a scale | Standard Deviation 26.33 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Fatigue Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 6 Day 1 | 1.46 score on a scale | Standard Deviation 21.13 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Fatigue Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | 4.44 score on a scale | Standard Deviation 24.68 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Fatigue Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 3 Day 1 | -1.63 score on a scale | Standard Deviation 20.32 |
| All Participants | Change From Baseline Over Time in Fatigue Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 16 Day 1 | 5.56 score on a scale | Standard Deviation 20.32 |
| All Participants | Change From Baseline Over Time in Fatigue Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | 1.39 score on a scale | Standard Deviation 27.86 |
| All Participants | Change From Baseline Over Time in Fatigue Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 7 Day 1 | 2.78 score on a scale | Standard Deviation 18.02 |
| All Participants | Change From Baseline Over Time in Fatigue Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 10 Day 1 | 3.03 score on a scale | Standard Deviation 21.74 |
| All Participants | Change From Baseline Over Time in Fatigue Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 13 Day 1 | 4.58 score on a scale | Standard Deviation 15.24 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Fatigue Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | 7.65 score on a scale | Standard Deviation 24.13 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Fatigue Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 7 Day 1 | 1.59 score on a scale | Standard Deviation 23.27 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Fatigue Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 10 Day 1 | -0.14 score on a scale | Standard Deviation 21.63 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Fatigue Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 13 Day 1 | 3.96 score on a scale | Standard Deviation 26.02 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Fatigue Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 16 Day 1 | 1.00 score on a scale | Standard Deviation 26.64 |
Secondary
Change From Baseline Over Time in Financial Difficulties Scale Score as Assessed by EORTC-QLQ-C30
EORTC QLQ-C30 consists of 30 questions that assess five aspects of participant functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), GHS and QoL, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) with a recall period of the previous week. Scale scores can be obtained for the multi-item scales. The financial difficulties scale items are scored on a 4-point scale (1=Not at All to 4=Very Much). Scores are linearly transformed on a scale of 0 to 100, with a high score on the scale indicating worst functioning. EORTC QLQ-C30 data was scored according to the EORTC scoring manual v3.0. In the event of incomplete data, if more than 50% of the constituent items were completed, a pro-rated score was computed. For subscales with less than 50% of the items completed, the subscale was considered as missing.
Time frame: Baseline, Day 1 of Cycles 3, 6, 7, 10, 13, 16 and End of Treatment (up to approximately 2.2 years)
Population: FAS included all randomized participants. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at specified timepoint.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Financial Difficulties Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | 24.24 score on a scale | Standard Deviation 44.95 |
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Financial Difficulties Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 3 Day 1 | 7.98 score on a scale | Standard Deviation 27.87 |
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Financial Difficulties Scale Score as Assessed by EORTC-QLQ-C30 | Baseline | 13.79 score on a scale | Standard Deviation 25.19 |
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Financial Difficulties Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 6 Day 1 | 11.11 score on a scale | Standard Deviation 32.33 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Financial Difficulties Scale Score as Assessed by EORTC-QLQ-C30 | Baseline | 20.39 score on a scale | Standard Deviation 31.33 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Financial Difficulties Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 6 Day 1 | 0.00 score on a scale | Standard Deviation 25.09 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Financial Difficulties Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | 0.00 score on a scale | Standard Deviation 35.14 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Financial Difficulties Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 3 Day 1 | -1.33 score on a scale | Standard Deviation 23.53 |
| All Participants | Change From Baseline Over Time in Financial Difficulties Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 16 Day 1 | -2.38 score on a scale | Standard Deviation 8.91 |
| All Participants | Change From Baseline Over Time in Financial Difficulties Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | -1.39 score on a scale | Standard Deviation 20.8 |
| All Participants | Change From Baseline Over Time in Financial Difficulties Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 7 Day 1 | 0.00 score on a scale | Standard Deviation 17.03 |
| All Participants | Change From Baseline Over Time in Financial Difficulties Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 10 Day 1 | 0.00 score on a scale | Standard Deviation 14.55 |
| All Participants | Change From Baseline Over Time in Financial Difficulties Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 13 Day 1 | -1.96 score on a scale | Standard Deviation 14.29 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Financial Difficulties Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | 5.70 score on a scale | Standard Deviation 29.51 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Financial Difficulties Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 7 Day 1 | -0.44 score on a scale | Standard Deviation 28.54 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Financial Difficulties Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 10 Day 1 | 1.65 score on a scale | Standard Deviation 27.34 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Financial Difficulties Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 13 Day 1 | 2.35 score on a scale | Standard Deviation 28.35 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Financial Difficulties Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 16 Day 1 | 5.47 score on a scale | Standard Deviation 26.33 |
Secondary
Change From Baseline Over Time in Health-related Quality of Life (HRQoL) Score as Assessed by GHS/QoL Scale of the EORTC-QLQ-C30
EORTC QLQ-C30 consists of 30 questions that assess participant functioning (physical, emotional, role, cognitive, and social), symptom scales (fatigue, nausea and vomiting, pain), global health/ QoL, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Change in HRQoL was assessed using participant responses to questions regarding Global Health Status (Q29: GHS; How would you rate your overall health during the past week?) and QoL (Q30: QoL; How would you rate your overall quality of life during the past week?) and were scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized. Scores range from 0-100. A higher score indicates a better outcome.
Time frame: Baseline, Day 1 of Cycles 3, 6, 7, 10, 13, 16 and End of Treatment (up to approximately 2.2 years)
Population: FAS included all randomized participants. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at specified timepoint.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Health-related Quality of Life (HRQoL) Score as Assessed by GHS/QoL Scale of the EORTC-QLQ-C30 | Change at End of Treatment | -28.79 score on a scale | Standard Deviation 26.71 |
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Health-related Quality of Life (HRQoL) Score as Assessed by GHS/QoL Scale of the EORTC-QLQ-C30 | Change at Cycle 3 Day 1 | 0.12 score on a scale | Standard Deviation 22.95 |
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Health-related Quality of Life (HRQoL) Score as Assessed by GHS/QoL Scale of the EORTC-QLQ-C30 | Baseline | 67.05 score on a scale | Standard Deviation 19.97 |
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Health-related Quality of Life (HRQoL) Score as Assessed by GHS/QoL Scale of the EORTC-QLQ-C30 | Change at Cycle 6 Day 1 | -2.49 score on a scale | Standard Deviation 18.83 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Health-related Quality of Life (HRQoL) Score as Assessed by GHS/QoL Scale of the EORTC-QLQ-C30 | Baseline | 64.80 score on a scale | Standard Deviation 21.45 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Health-related Quality of Life (HRQoL) Score as Assessed by GHS/QoL Scale of the EORTC-QLQ-C30 | Change at Cycle 6 Day 1 | -0.27 score on a scale | Standard Deviation 22.26 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Health-related Quality of Life (HRQoL) Score as Assessed by GHS/QoL Scale of the EORTC-QLQ-C30 | Change at End of Treatment | -11.67 score on a scale | Standard Deviation 19.72 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Health-related Quality of Life (HRQoL) Score as Assessed by GHS/QoL Scale of the EORTC-QLQ-C30 | Change at Cycle 3 Day 1 | -0.22 score on a scale | Standard Deviation 18.43 |
| All Participants | Change From Baseline Over Time in Health-related Quality of Life (HRQoL) Score as Assessed by GHS/QoL Scale of the EORTC-QLQ-C30 | Change at Cycle 16 Day 1 | -7.74 score on a scale | Standard Deviation 18.33 |
| All Participants | Change From Baseline Over Time in Health-related Quality of Life (HRQoL) Score as Assessed by GHS/QoL Scale of the EORTC-QLQ-C30 | Change at End of Treatment | -13.54 score on a scale | Standard Deviation 25.4 |
| All Participants | Change From Baseline Over Time in Health-related Quality of Life (HRQoL) Score as Assessed by GHS/QoL Scale of the EORTC-QLQ-C30 | Change at Cycle 7 Day 1 | -2.08 score on a scale | Standard Deviation 19.85 |
| All Participants | Change From Baseline Over Time in Health-related Quality of Life (HRQoL) Score as Assessed by GHS/QoL Scale of the EORTC-QLQ-C30 | Change at Cycle 10 Day 1 | -3.79 score on a scale | Standard Deviation 16.21 |
| All Participants | Change From Baseline Over Time in Health-related Quality of Life (HRQoL) Score as Assessed by GHS/QoL Scale of the EORTC-QLQ-C30 | Change at Cycle 13 Day 1 | -5.39 score on a scale | Standard Deviation 15.29 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Health-related Quality of Life (HRQoL) Score as Assessed by GHS/QoL Scale of the EORTC-QLQ-C30 | Change at End of Treatment | -4.76 score on a scale | Standard Deviation 22.56 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Health-related Quality of Life (HRQoL) Score as Assessed by GHS/QoL Scale of the EORTC-QLQ-C30 | Change at Cycle 7 Day 1 | 1.84 score on a scale | Standard Deviation 19.94 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Health-related Quality of Life (HRQoL) Score as Assessed by GHS/QoL Scale of the EORTC-QLQ-C30 | Change at Cycle 10 Day 1 | 1.73 score on a scale | Standard Deviation 17.65 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Health-related Quality of Life (HRQoL) Score as Assessed by GHS/QoL Scale of the EORTC-QLQ-C30 | Change at Cycle 13 Day 1 | 0.23 score on a scale | Standard Deviation 19.24 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Health-related Quality of Life (HRQoL) Score as Assessed by GHS/QoL Scale of the EORTC-QLQ-C30 | Change at Cycle 16 Day 1 | 3.23 score on a scale | Standard Deviation 21.07 |
Secondary
Change From Baseline Over Time in Insomnia Scale Score as Assessed by EORTC-QLQ-C30
EORTC QLQ-C30 consists of 30 questions that assess five aspects of participant functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), GHS and QoL, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) with a recall period of the previous week. Scale scores can be obtained for the multi-item scales. The insomnia scale items are scored on a 4-point scale (1=Not at All to 4=Very Much). Scores are linearly transformed on a scale of 0 to 100, with a high score on the scale indicating worst symptoms. EORTC QLQ-C30 data was scored according to the EORTC scoring manual v3.0. In the event of incomplete data, if more than 50% of the constituent items were completed, a pro-rated score was computed. For subscales with less than 50% of the items completed, the subscale was considered as missing.
Time frame: Baseline, Day 1 of Cycles 3, 6, 7, 10, 13, 16 and End of Treatment (up to approximately 2.2 years)
Population: FAS included all randomized participants. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at specified timepoint.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Insomnia Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | -2.78 score on a scale | Standard Deviation 17.16 |
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Insomnia Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 6 Day 1 | 0.57 score on a scale | Standard Deviation 23.77 |
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Insomnia Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 3 Day 1 | 0.46 score on a scale | Standard Deviation 26.53 |
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Insomnia Scale Score as Assessed by EORTC-QLQ-C30 | Baseline | 23.11 score on a scale | Standard Deviation 27.85 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Insomnia Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 3 Day 1 | -0.44 score on a scale | Standard Deviation 20.13 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Insomnia Scale Score as Assessed by EORTC-QLQ-C30 | Baseline | 28.63 score on a scale | Standard Deviation 31.77 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Insomnia Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | -13.33 score on a scale | Standard Deviation 35.83 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Insomnia Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 6 Day 1 | 2.19 score on a scale | Standard Deviation 27.13 |
| All Participants | Change From Baseline Over Time in Insomnia Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 16 Day 1 | 0.00 score on a scale | Standard Deviation 13.07 |
| All Participants | Change From Baseline Over Time in Insomnia Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 7 Day 1 | 15.28 score on a scale | Standard Deviation 32.57 |
| All Participants | Change From Baseline Over Time in Insomnia Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 10 Day 1 | 6.06 score on a scale | Standard Deviation 24.42 |
| All Participants | Change From Baseline Over Time in Insomnia Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 13 Day 1 | 15.69 score on a scale | Standard Deviation 20.81 |
| All Participants | Change From Baseline Over Time in Insomnia Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | 4.17 score on a scale | Standard Deviation 38.46 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Insomnia Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 16 Day 1 | 3.98 score on a scale | Standard Deviation 22.11 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Insomnia Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 10 Day 1 | 2.44 score on a scale | Standard Deviation 25 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Insomnia Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 7 Day 1 | 2.16 score on a scale | Standard Deviation 23.78 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Insomnia Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | 3.90 score on a scale | Standard Deviation 25.35 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Insomnia Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 13 Day 1 | 1.37 score on a scale | Standard Deviation 25.72 |
Secondary
Change From Baseline Over Time in Nausea and Vomiting Scale Score as Assessed by EORTC-QLQ-C30
EORTC QLQ-C30 consists of 30 questions that assess five aspects of participant functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), GHS and QoL, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) with a recall period of the previous week. Scale scores can be obtained for the multi-item scales. The symptom items are scored on a 4-point scale (1=Not at All to 4=Very Much). Scores are linearly transformed on a scale of 0 to 100, with a high score indicating worst symptoms. EORTC QLQ-C30 data was scored according to the EORTC scoring manual v3.0. In the event of incomplete data, if more than 50% of the constituent items were completed, a pro-rated score was computed. For subscales with less than 50% of the items completed, the subscale was considered as missing.
Time frame: Baseline, Day 1 of Cycles 3, 6, 7, 10, 13, 16 and End of Treatment (up to approximately 2.2 years)
Population: FAS included all randomized participants. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at specified timepoint.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Nausea and Vomiting Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | -3.03 score on a scale | Standard Deviation 16.36 |
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Nausea and Vomiting Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 3 Day 1 | 2.31 score on a scale | Standard Deviation 15.65 |
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Nausea and Vomiting Scale Score as Assessed by EORTC-QLQ-C30 | Baseline | 5.30 score on a scale | Standard Deviation 13.5 |
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Nausea and Vomiting Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 6 Day 1 | 2.01 score on a scale | Standard Deviation 12.9 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Nausea and Vomiting Scale Score as Assessed by EORTC-QLQ-C30 | Baseline | 5.88 score on a scale | Standard Deviation 14.48 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Nausea and Vomiting Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 6 Day 1 | 3.01 score on a scale | Standard Deviation 14.11 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Nausea and Vomiting Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | 6.67 score on a scale | Standard Deviation 23.83 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Nausea and Vomiting Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 3 Day 1 | 1.56 score on a scale | Standard Deviation 18.21 |
| All Participants | Change From Baseline Over Time in Nausea and Vomiting Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 16 Day 1 | 1.19 score on a scale | Standard Deviation 4.45 |
| All Participants | Change From Baseline Over Time in Nausea and Vomiting Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | 6.94 score on a scale | Standard Deviation 18.33 |
| All Participants | Change From Baseline Over Time in Nausea and Vomiting Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 7 Day 1 | 4.86 score on a scale | Standard Deviation 9.17 |
| All Participants | Change From Baseline Over Time in Nausea and Vomiting Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 10 Day 1 | 3.79 score on a scale | Standard Deviation 10.2 |
| All Participants | Change From Baseline Over Time in Nausea and Vomiting Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 13 Day 1 | 0.98 score on a scale | Standard Deviation 4.04 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Nausea and Vomiting Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | 1.73 score on a scale | Standard Deviation 12.56 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Nausea and Vomiting Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 7 Day 1 | -0.65 score on a scale | Standard Deviation 9.15 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Nausea and Vomiting Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 10 Day 1 | 1.02 score on a scale | Standard Deviation 9.57 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Nausea and Vomiting Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 13 Day 1 | 0.46 score on a scale | Standard Deviation 14.16 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Nausea and Vomiting Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 16 Day 1 | 0.75 score on a scale | Standard Deviation 13.11 |
Secondary
Change From Baseline Over Time in Pain Scale Score as Assessed by EORTC-QLQ-C30
EORTC QLQ-C30 consists of 30 questions that assess five aspects of participant functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), GHS and QoL, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) with a recall period of the previous week. Scale scores can be obtained for the multi-item scales. The symptom items are scored on a 4-point scale (1=Not at All to 4=Very Much). Scores are linearly transformed on a scale of 0 to 100, with a high score indicating worst symptoms. EORTC QLQ-C30 data was scored according to the EORTC scoring manual v3.0. In the event of incomplete data, if more than 50% of the constituent items were completed, a pro-rated score was computed. For subscales with less than 50% of the items completed, the subscale was considered as missing.
Time frame: Baseline, Day 1 of Cycles 3, 6, 7, 10, 13, 16 and End of Treatment (up to approximately 2.2 years)
Population: FAS included all randomized participants. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at specified timepoint.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Pain Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | 12.50 score on a scale | Standard Deviation 43.3 |
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Pain Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 3 Day 1 | 0.93 score on a scale | Standard Deviation 22.88 |
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Pain Scale Score as Assessed by EORTC-QLQ-C30 | Baseline | 22.16 score on a scale | Standard Deviation 25.23 |
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Pain Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 6 Day 1 | 4.02 score on a scale | Standard Deviation 23.22 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Pain Scale Score as Assessed by EORTC-QLQ-C30 | Baseline | 29.22 score on a scale | Standard Deviation 30.74 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Pain Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 6 Day 1 | -1.09 score on a scale | Standard Deviation 25.43 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Pain Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | -10.00 score on a scale | Standard Deviation 28.54 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Pain Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 3 Day 1 | -3.56 score on a scale | Standard Deviation 26.47 |
| All Participants | Change From Baseline Over Time in Pain Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 16 Day 1 | 4.76 score on a scale | Standard Deviation 32.31 |
| All Participants | Change From Baseline Over Time in Pain Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | 18.06 score on a scale | Standard Deviation 33.66 |
| All Participants | Change From Baseline Over Time in Pain Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 7 Day 1 | 4.17 score on a scale | Standard Deviation 28.34 |
| All Participants | Change From Baseline Over Time in Pain Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 10 Day 1 | 3.79 score on a scale | Standard Deviation 32.5 |
| All Participants | Change From Baseline Over Time in Pain Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 13 Day 1 | 7.84 score on a scale | Standard Deviation 35.9 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Pain Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | 6.28 score on a scale | Standard Deviation 30.35 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Pain Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 7 Day 1 | 1.52 score on a scale | Standard Deviation 28.89 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Pain Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 10 Day 1 | -1.22 score on a scale | Standard Deviation 26.42 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Pain Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 13 Day 1 | 1.14 score on a scale | Standard Deviation 25.81 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Pain Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 16 Day 1 | 1.24 score on a scale | Standard Deviation 28.32 |
Secondary
Change From Baseline Over Time in Physical Functioning Scale Score as Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC-QLQ-C30)
EORTC QLQ-C30 consists of 30 questions that assess five aspects of participant functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), global health status (GHS) and quality of life (QoL), and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) with a recall period of the previous week. Scale scores can be obtained for the multi-item scales. The functioning items are scored on a 4-point scale (1=Not at All to 4=Very Much). Scores are linearly transformed on a scale of 0 to 100, with a high score indicating better functioning. EORTC QLQ-C30 data was scored according to the EORTC scoring manual v3.0. In the event of incomplete data, if more than 50% of the constituent items were completed, a pro-rated score was computed. For subscales with less than 50% of the items completed, the subscale was considered as missing.
Time frame: Baseline, Day 1 of Cycles 3, 6, 7, 10, 13, 16 and End of Treatment (up to approximately 2.2 years)
Population: FAS included all randomized participants. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at specified timepoint.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Physical Functioning Scale Score as Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC-QLQ-C30) | Change at End of Treatment | -13.75 score on a scale | Standard Deviation 28.39 |
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Physical Functioning Scale Score as Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC-QLQ-C30) | Change at Cycle 3 Day 1 | -0.46 score on a scale | Standard Deviation 19.62 |
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Physical Functioning Scale Score as Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC-QLQ-C30) | Baseline | 75.00 score on a scale | Standard Deviation 19.79 |
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Physical Functioning Scale Score as Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC-QLQ-C30) | Change at Cycle 6 Day 1 | 0.00 score on a scale | Standard Deviation 16.19 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Physical Functioning Scale Score as Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC-QLQ-C30) | Baseline | 72.09 score on a scale | Standard Deviation 20.1 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Physical Functioning Scale Score as Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC-QLQ-C30) | Change at Cycle 6 Day 1 | -1.60 score on a scale | Standard Deviation 16.74 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Physical Functioning Scale Score as Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC-QLQ-C30) | Change at End of Treatment | -14.67 score on a scale | Standard Deviation 25.49 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Physical Functioning Scale Score as Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC-QLQ-C30) | Change at Cycle 3 Day 1 | -2.01 score on a scale | Standard Deviation 16 |
| All Participants | Change From Baseline Over Time in Physical Functioning Scale Score as Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC-QLQ-C30) | Change at Cycle 16 Day 1 | 0.48 score on a scale | Standard Deviation 16.22 |
| All Participants | Change From Baseline Over Time in Physical Functioning Scale Score as Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC-QLQ-C30) | Change at End of Treatment | -8.06 score on a scale | Standard Deviation 21.26 |
| All Participants | Change From Baseline Over Time in Physical Functioning Scale Score as Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC-QLQ-C30) | Change at Cycle 7 Day 1 | -2.22 score on a scale | Standard Deviation 13.85 |
| All Participants | Change From Baseline Over Time in Physical Functioning Scale Score as Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC-QLQ-C30) | Change at Cycle 10 Day 1 | 0.91 score on a scale | Standard Deviation 19.55 |
| All Participants | Change From Baseline Over Time in Physical Functioning Scale Score as Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC-QLQ-C30) | Change at Cycle 13 Day 1 | -5.10 score on a scale | Standard Deviation 19.93 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Physical Functioning Scale Score as Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC-QLQ-C30) | Change at End of Treatment | -3.92 score on a scale | Standard Deviation 21.67 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Physical Functioning Scale Score as Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC-QLQ-C30) | Change at Cycle 7 Day 1 | 0.03 score on a scale | Standard Deviation 15.39 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Physical Functioning Scale Score as Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC-QLQ-C30) | Change at Cycle 10 Day 1 | 2.06 score on a scale | Standard Deviation 16.64 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Physical Functioning Scale Score as Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC-QLQ-C30) | Change at Cycle 13 Day 1 | -0.43 score on a scale | Standard Deviation 17.98 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Physical Functioning Scale Score as Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC-QLQ-C30) | Change at Cycle 16 Day 1 | 1.03 score on a scale | Standard Deviation 15.77 |
Secondary
Change From Baseline Over Time in Role Functioning Scale Score as Assessed by EORTC-QLQ-C30
EORTC QLQ-C30 consists of 30 questions that assess five aspects of participant functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), GHS and QoL, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) with a recall period of the previous week. Scale scores can be obtained for the multi-item scales. The functioning items are scored on a 4-point scale (1=Not at All to 4=Very Much). Scores are linearly transformed on a scale of 0 to 100, with a high score indicating better functioning. EORTC QLQ-C30 data was scored according to the EORTC scoring manual v3.0. In the event of incomplete data, if more than 50% of the constituent items were completed, a pro-rated score was computed. For subscales with less than 50% of the items completed, the subscale was considered as missing.
Time frame: Baseline, Day 1 of Cycles 3, 6, 7, 10, 13, 16 and End of Treatment (up to approximately 2.2 years)
Population: FAS included all randomized participants. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at specified timepoint.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Role Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | -16.67 score on a scale | Standard Deviation 43.81 |
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Role Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 3 Day 1 | 1.16 score on a scale | Standard Deviation 29.25 |
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Role Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Baseline | 77.46 score on a scale | Standard Deviation 25.15 |
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Role Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 6 Day 1 | -2.01 score on a scale | Standard Deviation 26.13 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Role Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Baseline | 73.73 score on a scale | Standard Deviation 27.86 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Role Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 6 Day 1 | -1.64 score on a scale | Standard Deviation 24.1 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Role Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | -15.00 score on a scale | Standard Deviation 24.15 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Role Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 3 Day 1 | -1.33 score on a scale | Standard Deviation 21.88 |
| All Participants | Change From Baseline Over Time in Role Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 16 Day 1 | -2.38 score on a scale | Standard Deviation 14.41 |
| All Participants | Change From Baseline Over Time in Role Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | -9.72 score on a scale | Standard Deviation 24.04 |
| All Participants | Change From Baseline Over Time in Role Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 7 Day 1 | -8.33 score on a scale | Standard Deviation 18.39 |
| All Participants | Change From Baseline Over Time in Role Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 10 Day 1 | -6.82 score on a scale | Standard Deviation 23.94 |
| All Participants | Change From Baseline Over Time in Role Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 13 Day 1 | -6.86 score on a scale | Standard Deviation 21.29 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Role Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | -8.01 score on a scale | Standard Deviation 25.88 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Role Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 7 Day 1 | -5.41 score on a scale | Standard Deviation 26 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Role Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 10 Day 1 | -2.03 score on a scale | Standard Deviation 24.2 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Role Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 13 Day 1 | -1.60 score on a scale | Standard Deviation 26.52 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Role Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 16 Day 1 | -2.74 score on a scale | Standard Deviation 26.84 |
Secondary
Change From Baseline Over Time in Social Functioning Scale Score as Assessed by EORTC-QLQ-C30
EORTC QLQ-C30 consists of 30 questions that assess five aspects of participant functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), GHS and QoL, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) with a recall period of the previous week. Scale scores can be obtained for the multi-item scales. The functioning items are scored on a 4-point scale (1=Not at All to 4=Very Much). Scores are linearly transformed on a scale of 0 to 100, with a high score indicating better functioning. EORTC QLQ-C30 data was scored according to the EORTC scoring manual v3.0. In the event of incomplete data, if more than 50% of the constituent items were completed, a pro-rated score was computed. For subscales with less than 50% of the items completed, the subscale was considered as missing.
Time frame: Baseline, Day 1 of Cycles 3, 6, 7, 10, 13, 16 and End of Treatment (up to approximately 2.2 years)
Population: FAS included all randomized participants. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at specified timepoint.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Social Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | -12.50 score on a scale | Standard Deviation 46.13 |
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Social Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 3 Day 1 | 3.70 score on a scale | Standard Deviation 23.61 |
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Social Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Baseline | 82.95 score on a scale | Standard Deviation 23.02 |
| Crossover Atezolizumab IV/SC | Change From Baseline Over Time in Social Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 6 Day 1 | -2.87 score on a scale | Standard Deviation 24.81 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Social Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Baseline | 82.35 score on a scale | Standard Deviation 22.76 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Social Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 6 Day 1 | -1.91 score on a scale | Standard Deviation 22.38 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Social Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | -15.00 score on a scale | Standard Deviation 29.87 |
| Crossover Atezolizumab SC/IV | Change From Baseline Over Time in Social Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 3 Day 1 | -3.56 score on a scale | Standard Deviation 21.1 |
| All Participants | Change From Baseline Over Time in Social Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 16 Day 1 | -5.95 score on a scale | Standard Deviation 24.11 |
| All Participants | Change From Baseline Over Time in Social Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | -15.28 score on a scale | Standard Deviation 24.53 |
| All Participants | Change From Baseline Over Time in Social Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 7 Day 1 | -6.25 score on a scale | Standard Deviation 27.72 |
| All Participants | Change From Baseline Over Time in Social Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 10 Day 1 | -3.79 score on a scale | Standard Deviation 27.18 |
| All Participants | Change From Baseline Over Time in Social Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 13 Day 1 | -3.92 score on a scale | Standard Deviation 17.21 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Social Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at End of Treatment | -4.98 score on a scale | Standard Deviation 27.84 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Social Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 7 Day 1 | 0.22 score on a scale | Standard Deviation 21.71 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Social Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 10 Day 1 | -0.20 score on a scale | Standard Deviation 25.32 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Social Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 13 Day 1 | -0.46 score on a scale | Standard Deviation 23.57 |
| Continuation Atezolizumab SC | Change From Baseline Over Time in Social Functioning Scale Score as Assessed by EORTC-QLQ-C30 | Change at Cycle 16 Day 1 | 0.50 score on a scale | Standard Deviation 19.67 |
Secondary
Duration of Treatment Administration Activities According to HCPs Response to Perception of Time, Assessed Using Question 1 of HCPQs - Treatment Room
The HCPQ-Treatment Room Question 1 was completed for every participant at each treatment cycle of the Treatment Crossover Period (Cycles 1-6,i.e., 3 cycles of atezolizumab IV followed by 3 cycles of atezolizumab SC/vice versa) by HCPs who administered treatment to the study participants. HCPs responded to following parts of Question 1 that sought to evaluate the amount of time it took to complete activities related to treatment administration: If new IV access was needed for this cycle of treatment, please indicate what type of IV access was provided (central venous catheter, peripherally inserted central catheter (PICC)/peripheral vein cannulation) & how long (in minutes) this took to set up (only for participants receiving IV treatment)? How long (in minutes) did it take to administer the treatment, i.e. total infusion duration? How long (in minutes) was the participant in the treatment room for in total? Durations with non-zero HCP responders have been reported here.
Time frame: Day 1 of Cycles 1 to 6 (cycle length=21 days)
Population: Overall number analyzed included HCPs who completed Question 1 of the survey. For the questions related to IV access, the number analyzed only includes number of HCP responders for participants who required new IV access at a given treatment cycle. The number analyzed included HCPs who completed Question 1 of the survey at the specified treatment cycles. Percentages have been rounded off.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Crossover Atezolizumab IV/SC | Duration of Treatment Administration Activities According to HCPs Response to Perception of Time, Assessed Using Question 1 of HCPQs - Treatment Room | Cycle 2: Duration of Peripherally Inserted Central Catheter set up? | 30.0 minutes |
| Crossover Atezolizumab IV/SC | Duration of Treatment Administration Activities According to HCPs Response to Perception of Time, Assessed Using Question 1 of HCPQs - Treatment Room | Cycle 2: Duration of Peripheral Vein Cannulation set up? | 5.0 minutes |
| Crossover Atezolizumab IV/SC | Duration of Treatment Administration Activities According to HCPs Response to Perception of Time, Assessed Using Question 1 of HCPQs - Treatment Room | Cycle 2: How Long did it Take to Administer the Treatment? | 30.0 minutes |
| Crossover Atezolizumab IV/SC | Duration of Treatment Administration Activities According to HCPs Response to Perception of Time, Assessed Using Question 1 of HCPQs - Treatment Room | Cycle 4: How Long did it Take to Administer the Treatment? | 8.0 minutes |
| Crossover Atezolizumab IV/SC | Duration of Treatment Administration Activities According to HCPs Response to Perception of Time, Assessed Using Question 1 of HCPQs - Treatment Room | Cycle 1: How Long did it Take to Administer the Treatment? | 60.0 minutes |
| Crossover Atezolizumab IV/SC | Duration of Treatment Administration Activities According to HCPs Response to Perception of Time, Assessed Using Question 1 of HCPQs - Treatment Room | Cycle 4: How Long was the Participant in the Treatment Room in Total? | 45.0 minutes |
| Crossover Atezolizumab IV/SC | Duration of Treatment Administration Activities According to HCPs Response to Perception of Time, Assessed Using Question 1 of HCPQs - Treatment Room | Cycle 2: How Long was the Participant in the Treatment Room in Total? | 75.0 minutes |
| Crossover Atezolizumab IV/SC | Duration of Treatment Administration Activities According to HCPs Response to Perception of Time, Assessed Using Question 1 of HCPQs - Treatment Room | Cycle 1: Duration of Peripherally Inserted Central Catheter set up? | 30.0 minutes |
| Crossover Atezolizumab IV/SC | Duration of Treatment Administration Activities According to HCPs Response to Perception of Time, Assessed Using Question 1 of HCPQs - Treatment Room | Cycle 3: Duration of Central Venous Catheter set up? | 61.0 minutes |
| Crossover Atezolizumab IV/SC | Duration of Treatment Administration Activities According to HCPs Response to Perception of Time, Assessed Using Question 1 of HCPQs - Treatment Room | Cycle 3: Duration of Peripherally Inserted Central Catheter set up? | 17.5 minutes |
| Crossover Atezolizumab IV/SC | Duration of Treatment Administration Activities According to HCPs Response to Perception of Time, Assessed Using Question 1 of HCPQs - Treatment Room | Cycle 5: How Long did it Take to Administer the Treatment? | 6.0 minutes |
| Crossover Atezolizumab IV/SC | Duration of Treatment Administration Activities According to HCPs Response to Perception of Time, Assessed Using Question 1 of HCPQs - Treatment Room | Cycle 3: Duration of Peripheral Vein Cannulation set up? | 5.0 minutes |
| Crossover Atezolizumab IV/SC | Duration of Treatment Administration Activities According to HCPs Response to Perception of Time, Assessed Using Question 1 of HCPQs - Treatment Room | Cycle 5: How Long was the Participant in the Treatment Room in Total? | 35.0 minutes |
| Crossover Atezolizumab IV/SC | Duration of Treatment Administration Activities According to HCPs Response to Perception of Time, Assessed Using Question 1 of HCPQs - Treatment Room | Cycle 3: How Long did it Take to Administer the Treatment? | 30.0 minutes |
| Crossover Atezolizumab IV/SC | Duration of Treatment Administration Activities According to HCPs Response to Perception of Time, Assessed Using Question 1 of HCPQs - Treatment Room | Cycle 1: How Long was the Participant in the Treatment Room in Total? | 92.0 minutes |
| Crossover Atezolizumab IV/SC | Duration of Treatment Administration Activities According to HCPs Response to Perception of Time, Assessed Using Question 1 of HCPQs - Treatment Room | Cycle 3: How Long was the Participant in the Treatment Room in Total? | 70.0 minutes |
| Crossover Atezolizumab IV/SC | Duration of Treatment Administration Activities According to HCPs Response to Perception of Time, Assessed Using Question 1 of HCPQs - Treatment Room | Cycle 6: How Long did it Take to Administer the Treatment? | 7.0 minutes |
| Crossover Atezolizumab IV/SC | Duration of Treatment Administration Activities According to HCPs Response to Perception of Time, Assessed Using Question 1 of HCPQs - Treatment Room | Cycle 1: Duration of Peripheral Vein Cannulation set up? | 5.0 minutes |
| Crossover Atezolizumab IV/SC | Duration of Treatment Administration Activities According to HCPs Response to Perception of Time, Assessed Using Question 1 of HCPQs - Treatment Room | Cycle 6: How Long was the Participant in the Treatment Room in Total? | 37.5 minutes |
| Crossover Atezolizumab IV/SC | Duration of Treatment Administration Activities According to HCPs Response to Perception of Time, Assessed Using Question 1 of HCPQs - Treatment Room | Cycle 1: Duration of Central Venous Catheter set up? | 5 minutes |
| Crossover Atezolizumab SC/IV | Duration of Treatment Administration Activities According to HCPs Response to Perception of Time, Assessed Using Question 1 of HCPQs - Treatment Room | Cycle 6: How Long was the Participant in the Treatment Room in Total? | 61.0 minutes |
| Crossover Atezolizumab SC/IV | Duration of Treatment Administration Activities According to HCPs Response to Perception of Time, Assessed Using Question 1 of HCPQs - Treatment Room | Cycle 1: How Long did it Take to Administer the Treatment? | 8.0 minutes |
| Crossover Atezolizumab SC/IV | Duration of Treatment Administration Activities According to HCPs Response to Perception of Time, Assessed Using Question 1 of HCPQs - Treatment Room | Cycle 1: How Long was the Participant in the Treatment Room in Total? | 55.0 minutes |
| Crossover Atezolizumab SC/IV | Duration of Treatment Administration Activities According to HCPs Response to Perception of Time, Assessed Using Question 1 of HCPQs - Treatment Room | Cycle 2: How Long did it Take to Administer the Treatment? | 6.0 minutes |
| Crossover Atezolizumab SC/IV | Duration of Treatment Administration Activities According to HCPs Response to Perception of Time, Assessed Using Question 1 of HCPQs - Treatment Room | Cycle 2: How Long was the Participant in the Treatment Room in Total? | 41.0 minutes |
| Crossover Atezolizumab SC/IV | Duration of Treatment Administration Activities According to HCPs Response to Perception of Time, Assessed Using Question 1 of HCPQs - Treatment Room | Cycle 3: How Long did it Take to Administer the Treatment? | 6.0 minutes |
| Crossover Atezolizumab SC/IV | Duration of Treatment Administration Activities According to HCPs Response to Perception of Time, Assessed Using Question 1 of HCPQs - Treatment Room | Cycle 3: How Long was the Participant in the Treatment Room in Total? | 49.0 minutes |
| Crossover Atezolizumab SC/IV | Duration of Treatment Administration Activities According to HCPs Response to Perception of Time, Assessed Using Question 1 of HCPQs - Treatment Room | Cycle 4: Duration of Central Venous Catheter set up? | 10.0 minutes |
| Crossover Atezolizumab SC/IV | Duration of Treatment Administration Activities According to HCPs Response to Perception of Time, Assessed Using Question 1 of HCPQs - Treatment Room | Cycle 4: Duration of Peripherally Inserted Central Catheter set up? | 30.0 minutes |
| Crossover Atezolizumab SC/IV | Duration of Treatment Administration Activities According to HCPs Response to Perception of Time, Assessed Using Question 1 of HCPQs - Treatment Room | Cycle 4: Duration of Peripheral Vein Cannulation set up? | 5.0 minutes |
| Crossover Atezolizumab SC/IV | Duration of Treatment Administration Activities According to HCPs Response to Perception of Time, Assessed Using Question 1 of HCPQs - Treatment Room | Cycle 4: How Long did it Take to Administer the Treatment? | 60.0 minutes |
| Crossover Atezolizumab SC/IV | Duration of Treatment Administration Activities According to HCPs Response to Perception of Time, Assessed Using Question 1 of HCPQs - Treatment Room | Cycle 4: How Long was the Participant in the Treatment Room in Total? | 97.0 minutes |
| Crossover Atezolizumab SC/IV | Duration of Treatment Administration Activities According to HCPs Response to Perception of Time, Assessed Using Question 1 of HCPQs - Treatment Room | Cycle 5: Duration of Central Venous Catheter set up? | 5.0 minutes |
| Crossover Atezolizumab SC/IV | Duration of Treatment Administration Activities According to HCPs Response to Perception of Time, Assessed Using Question 1 of HCPQs - Treatment Room | Cycle 5: Duration of Peripherally Inserted Central Catheter set up? | 22.5 minutes |
| Crossover Atezolizumab SC/IV | Duration of Treatment Administration Activities According to HCPs Response to Perception of Time, Assessed Using Question 1 of HCPQs - Treatment Room | Cycle 5: Duration of Peripheral Vein Cannulation set up? | 5.0 minutes |
| Crossover Atezolizumab SC/IV | Duration of Treatment Administration Activities According to HCPs Response to Perception of Time, Assessed Using Question 1 of HCPQs - Treatment Room | Cycle 5: How Long did it Take to Administer the Treatment? | 30.0 minutes |
| Crossover Atezolizumab SC/IV | Duration of Treatment Administration Activities According to HCPs Response to Perception of Time, Assessed Using Question 1 of HCPQs - Treatment Room | Cycle 5: How Long was the Participant in the Treatment Room in Total? | 71.0 minutes |
| Crossover Atezolizumab SC/IV | Duration of Treatment Administration Activities According to HCPs Response to Perception of Time, Assessed Using Question 1 of HCPQs - Treatment Room | Cycle 6: Duration of Peripherally Inserted Central Catheter set up? | 12.5 minutes |
| Crossover Atezolizumab SC/IV | Duration of Treatment Administration Activities According to HCPs Response to Perception of Time, Assessed Using Question 1 of HCPQs - Treatment Room | Cycle 6: Duration of Peripheral Vein Cannulation set up? | 5.0 minutes |
| Crossover Atezolizumab SC/IV | Duration of Treatment Administration Activities According to HCPs Response to Perception of Time, Assessed Using Question 1 of HCPQs - Treatment Room | Cycle 6: How Long did it Take to Administer the Treatment? | 30.0 minutes |
Secondary
Duration of Treatment Preparation According to Healthcare Professionals (HCPs) Response to Perception of Time, Assessed Using Question 1 of Healthcare Professional Questionnaires (HCPQs) - Drug Preparation Area
The HCPQ- Drug Preparation Area Question 1 was completed by the HCPs within the pharmacy/drug preparation area where atezolizumab IV reconstitution or atezolizumab SC was prepared before the actual drug administration took place. The HCPQs were completed for every participant at each treatment cycle (Cycles 1-6, i.e., 3 cycles of atezolizumab IV followed by 3 cycles of atezolizumab SC or vice versa) of the treatment cross-over period. HCPs responded to the following parts of Question 1 that sought to evaluate the amount of time it took to prepare the IV infusion/SC injection of atezolizumab: How long (in minutes) did it take to prepare the treatment for use?
Time frame: Day 1 of Cycles 1 to 6 (cycle length= 21 days)
Population: Overall number analyzed included HCPs who completed Question 1 of the survey. The number analyzed included HCPs who completed Question 1 of the survey at the specified treatment cycles.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Crossover Atezolizumab IV/SC | Duration of Treatment Preparation According to Healthcare Professionals (HCPs) Response to Perception of Time, Assessed Using Question 1 of Healthcare Professional Questionnaires (HCPQs) - Drug Preparation Area | Cycle 1 | 5.0 minutes |
| Crossover Atezolizumab IV/SC | Duration of Treatment Preparation According to Healthcare Professionals (HCPs) Response to Perception of Time, Assessed Using Question 1 of Healthcare Professional Questionnaires (HCPQs) - Drug Preparation Area | Cycle 2 | 5.0 minutes |
| Crossover Atezolizumab IV/SC | Duration of Treatment Preparation According to Healthcare Professionals (HCPs) Response to Perception of Time, Assessed Using Question 1 of Healthcare Professional Questionnaires (HCPQs) - Drug Preparation Area | Cycle 3 | 5.0 minutes |
| Crossover Atezolizumab IV/SC | Duration of Treatment Preparation According to Healthcare Professionals (HCPs) Response to Perception of Time, Assessed Using Question 1 of Healthcare Professional Questionnaires (HCPQs) - Drug Preparation Area | Cycle 4 | 5.0 minutes |
| Crossover Atezolizumab IV/SC | Duration of Treatment Preparation According to Healthcare Professionals (HCPs) Response to Perception of Time, Assessed Using Question 1 of Healthcare Professional Questionnaires (HCPQs) - Drug Preparation Area | Cycle 5 | 5.0 minutes |
| Crossover Atezolizumab IV/SC | Duration of Treatment Preparation According to Healthcare Professionals (HCPs) Response to Perception of Time, Assessed Using Question 1 of Healthcare Professional Questionnaires (HCPQs) - Drug Preparation Area | Cycle 6 | 5.0 minutes |
| Crossover Atezolizumab SC/IV | Duration of Treatment Preparation According to Healthcare Professionals (HCPs) Response to Perception of Time, Assessed Using Question 1 of Healthcare Professional Questionnaires (HCPQs) - Drug Preparation Area | Cycle 5 | 5.0 minutes |
| Crossover Atezolizumab SC/IV | Duration of Treatment Preparation According to Healthcare Professionals (HCPs) Response to Perception of Time, Assessed Using Question 1 of Healthcare Professional Questionnaires (HCPQs) - Drug Preparation Area | Cycle 1 | 5.0 minutes |
| Crossover Atezolizumab SC/IV | Duration of Treatment Preparation According to Healthcare Professionals (HCPs) Response to Perception of Time, Assessed Using Question 1 of Healthcare Professional Questionnaires (HCPQs) - Drug Preparation Area | Cycle 4 | 5.0 minutes |
| Crossover Atezolizumab SC/IV | Duration of Treatment Preparation According to Healthcare Professionals (HCPs) Response to Perception of Time, Assessed Using Question 1 of Healthcare Professional Questionnaires (HCPQs) - Drug Preparation Area | Cycle 2 | 5.0 minutes |
| Crossover Atezolizumab SC/IV | Duration of Treatment Preparation According to Healthcare Professionals (HCPs) Response to Perception of Time, Assessed Using Question 1 of Healthcare Professional Questionnaires (HCPQs) - Drug Preparation Area | Cycle 6 | 5.0 minutes |
| Crossover Atezolizumab SC/IV | Duration of Treatment Preparation According to Healthcare Professionals (HCPs) Response to Perception of Time, Assessed Using Question 1 of Healthcare Professional Questionnaires (HCPQs) - Drug Preparation Area | Cycle 3 | 4.5 minutes |
Secondary
Number of Participants by Their Level of Satisfaction With Atezolizumab SC and Atezolizumab IV Assessed Using Therapy Administration Satisfaction Questionnaire - Subcutaneous (TASQ-SC) and Intravenous (TASQ-IV)
TASQ is a 12-item, participant-reported questionnaire measuring the impact of each mode of treatment administration (TASQ-IV for IV treatment and TASQ-SC for SC treatment) on five domains: Physical Impact, Psychological Impact, Impact on Activities of Daily Living, Convenience, and Satisfaction. TASQ-IV/-SC was administered at treatment Cycles 3 and 6 according to the order of treatment received per arm during the Crossover Period. Participants satisfaction was assessed based on the Question 1 of TASQ-IV/SC which asks participants about their satisfaction with respect to route of administration (very satisfied, satisfied, neither satisfied nor dissatisfied, dissatisfied, participant did not answer the question). Question 1 - TASQ- IV (How satisfied or dissatisfied were you with the IV infusion?) and TASQ- SC (How satisfied or dissatisfied were you with the SC injection?)
Time frame: Cycles 3 Day 1 and Cycle 6 Day 1 (cycle length=21 days)
Population: FAS included all randomized participants. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants who answered Question 1 of TASQ IV/SC.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Crossover Atezolizumab IV/SC | Number of Participants by Their Level of Satisfaction With Atezolizumab SC and Atezolizumab IV Assessed Using Therapy Administration Satisfaction Questionnaire - Subcutaneous (TASQ-SC) and Intravenous (TASQ-IV) | TASQ- IV- Very Satisfied | 25 Participants |
| Crossover Atezolizumab IV/SC | Number of Participants by Their Level of Satisfaction With Atezolizumab SC and Atezolizumab IV Assessed Using Therapy Administration Satisfaction Questionnaire - Subcutaneous (TASQ-SC) and Intravenous (TASQ-IV) | TASQ- IV- Satisfied | 31 Participants |
| Crossover Atezolizumab IV/SC | Number of Participants by Their Level of Satisfaction With Atezolizumab SC and Atezolizumab IV Assessed Using Therapy Administration Satisfaction Questionnaire - Subcutaneous (TASQ-SC) and Intravenous (TASQ-IV) | TASQ- IV- Neither Satisfied nor Dissatisfied | 17 Participants |
| Crossover Atezolizumab IV/SC | Number of Participants by Their Level of Satisfaction With Atezolizumab SC and Atezolizumab IV Assessed Using Therapy Administration Satisfaction Questionnaire - Subcutaneous (TASQ-SC) and Intravenous (TASQ-IV) | TASQ- IV- Dissatisfied | 1 Participants |
| Crossover Atezolizumab IV/SC | Number of Participants by Their Level of Satisfaction With Atezolizumab SC and Atezolizumab IV Assessed Using Therapy Administration Satisfaction Questionnaire - Subcutaneous (TASQ-SC) and Intravenous (TASQ-IV) | TASQ- IV- Very Dissatisfied | 0 Participants |
| Crossover Atezolizumab IV/SC | Number of Participants by Their Level of Satisfaction With Atezolizumab SC and Atezolizumab IV Assessed Using Therapy Administration Satisfaction Questionnaire - Subcutaneous (TASQ-SC) and Intravenous (TASQ-IV) | TASQ- IV- Participant did not Answer Question | 0 Participants |
| Crossover Atezolizumab IV/SC | Number of Participants by Their Level of Satisfaction With Atezolizumab SC and Atezolizumab IV Assessed Using Therapy Administration Satisfaction Questionnaire - Subcutaneous (TASQ-SC) and Intravenous (TASQ-IV) | TASQ- SC- Very Satisfied | 22 Participants |
| Crossover Atezolizumab IV/SC | Number of Participants by Their Level of Satisfaction With Atezolizumab SC and Atezolizumab IV Assessed Using Therapy Administration Satisfaction Questionnaire - Subcutaneous (TASQ-SC) and Intravenous (TASQ-IV) | TASQ- SC- Satisfied | 21 Participants |
| Crossover Atezolizumab IV/SC | Number of Participants by Their Level of Satisfaction With Atezolizumab SC and Atezolizumab IV Assessed Using Therapy Administration Satisfaction Questionnaire - Subcutaneous (TASQ-SC) and Intravenous (TASQ-IV) | TASQ- SC- Neither Satisfied nor Dissatisfied | 9 Participants |
| Crossover Atezolizumab IV/SC | Number of Participants by Their Level of Satisfaction With Atezolizumab SC and Atezolizumab IV Assessed Using Therapy Administration Satisfaction Questionnaire - Subcutaneous (TASQ-SC) and Intravenous (TASQ-IV) | TASQ- SC- Dissatisfied | 3 Participants |
| Crossover Atezolizumab IV/SC | Number of Participants by Their Level of Satisfaction With Atezolizumab SC and Atezolizumab IV Assessed Using Therapy Administration Satisfaction Questionnaire - Subcutaneous (TASQ-SC) and Intravenous (TASQ-IV) | TASQ- SC- Very Dissatisfied | 1 Participants |
| Crossover Atezolizumab IV/SC | Number of Participants by Their Level of Satisfaction With Atezolizumab SC and Atezolizumab IV Assessed Using Therapy Administration Satisfaction Questionnaire - Subcutaneous (TASQ-SC) and Intravenous (TASQ-IV) | TASQ- SC- Participant did not Answer Question | 0 Participants |
| Crossover Atezolizumab SC/IV | Number of Participants by Their Level of Satisfaction With Atezolizumab SC and Atezolizumab IV Assessed Using Therapy Administration Satisfaction Questionnaire - Subcutaneous (TASQ-SC) and Intravenous (TASQ-IV) | TASQ- SC- Very Dissatisfied | 0 Participants |
| Crossover Atezolizumab SC/IV | Number of Participants by Their Level of Satisfaction With Atezolizumab SC and Atezolizumab IV Assessed Using Therapy Administration Satisfaction Questionnaire - Subcutaneous (TASQ-SC) and Intravenous (TASQ-IV) | TASQ- IV- Very Satisfied | 10 Participants |
| Crossover Atezolizumab SC/IV | Number of Participants by Their Level of Satisfaction With Atezolizumab SC and Atezolizumab IV Assessed Using Therapy Administration Satisfaction Questionnaire - Subcutaneous (TASQ-SC) and Intravenous (TASQ-IV) | TASQ- SC- Very Satisfied | 30 Participants |
| Crossover Atezolizumab SC/IV | Number of Participants by Their Level of Satisfaction With Atezolizumab SC and Atezolizumab IV Assessed Using Therapy Administration Satisfaction Questionnaire - Subcutaneous (TASQ-SC) and Intravenous (TASQ-IV) | TASQ- IV- Satisfied | 34 Participants |
| Crossover Atezolizumab SC/IV | Number of Participants by Their Level of Satisfaction With Atezolizumab SC and Atezolizumab IV Assessed Using Therapy Administration Satisfaction Questionnaire - Subcutaneous (TASQ-SC) and Intravenous (TASQ-IV) | TASQ- SC- Dissatisfied | 0 Participants |
| Crossover Atezolizumab SC/IV | Number of Participants by Their Level of Satisfaction With Atezolizumab SC and Atezolizumab IV Assessed Using Therapy Administration Satisfaction Questionnaire - Subcutaneous (TASQ-SC) and Intravenous (TASQ-IV) | TASQ- IV- Neither Satisfied nor Dissatisfied | 11 Participants |
| Crossover Atezolizumab SC/IV | Number of Participants by Their Level of Satisfaction With Atezolizumab SC and Atezolizumab IV Assessed Using Therapy Administration Satisfaction Questionnaire - Subcutaneous (TASQ-SC) and Intravenous (TASQ-IV) | TASQ- SC- Satisfied | 36 Participants |
| Crossover Atezolizumab SC/IV | Number of Participants by Their Level of Satisfaction With Atezolizumab SC and Atezolizumab IV Assessed Using Therapy Administration Satisfaction Questionnaire - Subcutaneous (TASQ-SC) and Intravenous (TASQ-IV) | TASQ- IV- Dissatisfied | 1 Participants |
| Crossover Atezolizumab SC/IV | Number of Participants by Their Level of Satisfaction With Atezolizumab SC and Atezolizumab IV Assessed Using Therapy Administration Satisfaction Questionnaire - Subcutaneous (TASQ-SC) and Intravenous (TASQ-IV) | TASQ- SC- Participant did not Answer Question | 0 Participants |
| Crossover Atezolizumab SC/IV | Number of Participants by Their Level of Satisfaction With Atezolizumab SC and Atezolizumab IV Assessed Using Therapy Administration Satisfaction Questionnaire - Subcutaneous (TASQ-SC) and Intravenous (TASQ-IV) | TASQ- IV- Very Dissatisfied | 3 Participants |
| Crossover Atezolizumab SC/IV | Number of Participants by Their Level of Satisfaction With Atezolizumab SC and Atezolizumab IV Assessed Using Therapy Administration Satisfaction Questionnaire - Subcutaneous (TASQ-SC) and Intravenous (TASQ-IV) | TASQ- SC- Neither Satisfied nor Dissatisfied | 5 Participants |
| Crossover Atezolizumab SC/IV | Number of Participants by Their Level of Satisfaction With Atezolizumab SC and Atezolizumab IV Assessed Using Therapy Administration Satisfaction Questionnaire - Subcutaneous (TASQ-SC) and Intravenous (TASQ-IV) | TASQ- IV- Participant did not Answer Question | 0 Participants |
Secondary
Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area
HCPs within pharmacy/drug preparation area responded to HCPQ-Drug Preparation Area Question 2 at Cycle 6 of Treatment Crossover Period for every participant: If all IV infusions are switched to SC, please indicate how strongly you agree/disagree with each of following statements: a=Staff will have increased availability for other tasks in pharmacy; b=Administrative procedures around atezolizumab SC will require less time; c=Atezolizumab SC formulations will provide more flexibility for staff in managing their workload; d=Due to ready-to-use atezolizumab SC formulations, potential dosing errors will be avoided; e=Due to ready-to-use atezolizumab SC formulations, there will be less drug wastage; f=Without having to reconstitute the drug, less storage space for atezolizumab SC related supplies will be required in pharmacy; g=Preparation procedures & associated time staff time commitment will be reduced, h=It will ease drug administration for participants with difficult venous access.
Time frame: Cycle 6 Day 1 (cycle length=21 days)
Population: Overall number analyzed included HCPs who completed Question 2 of the survey at treatment Cycle 6. Percentages have been rounded off.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | c=Strongly Disagree | 0 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | a=Disagree | 7.0 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | a=Neutral | 21.1 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | a=Agree | 24.6 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | a=Strongly Agree | 31.6 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | a=Not Applicable | 3.5 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | a=Missing | 5.3 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | b=Strongly Disagree | 7.0 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | b=Disagree | 14.0 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | b=Neutral | 29.8 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | b=Agree | 12.3 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | b=Strongly Agree | 24.6 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | b=Not Applicable | 7.0 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | b=Missing | 5.3 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | a=Strongly Disagree | 7.0 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | c=Disagree | 8.8 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | c=Neutral | 29.8 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | c=Agree | 26.3 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | c=Strongly Agree | 26.3 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | c=Not Applicable | 3.5 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | c=Missing | 5.3 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | d=Strongly Disagree | 12.3 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | d=Disagree | 12.3 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | d=Neutral | 22.8 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | d=Agree | 15.8 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | d=Strongly Agree | 28.1 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | d=Not Applicable | 3.5 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | d=Missing | 5.3 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | e=Strongly Disagree | 1.8 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | e=Disagree | 19.3 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | e=Neutral | 14.0 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | e=Agree | 29.8 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | e=Strongly Agree | 26.3 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | e=Not Applicable | 3.5 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | e=Missing | 5.3 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | f=Strongly Disagree | 0 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | f=Disagree | 10.5 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | f=Neutral | 33.3 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | f=Agree | 21.1 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | f=Strongly Agree | 26.3 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | f=Not Applicable | 3.5 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | f=Missing | 5.3 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | g=Strongly Disagree | 5.3 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | g=Disagree | 5.3 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | g=Neutral | 26.3 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | g=Agree | 26.3 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | g=Strongly Agree | 28.1 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | g=Not Applicable | 3.5 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | g=Missing | 5.3 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | h=Strongly Disagree | 0 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | h=Disagree | 0 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | h=Neutral | 10.5 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | h=Agree | 40.4 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | h=Strongly Agree | 28.1 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | h=Not Applicable | 15.8 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | h=Missing | 5.3 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | h=Agree | 38.3 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | a=Strongly Disagree | 10.0 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | e=Strongly Disagree | 0 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | a=Disagree | 0 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | g=Strongly Disagree | 11.7 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | a=Neutral | 31.7 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | e=Disagree | 11.7 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | a=Agree | 20.0 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | h=Strongly Disagree | 0 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | a=Strongly Agree | 25.0 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | e=Neutral | 26.7 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | a=Not Applicable | 1.7 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | g=Disagree | 1.7 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | a=Missing | 11.7 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | e=Agree | 38.3 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | b=Strongly Disagree | 10.0 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | h=Not Applicable | 10.0 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | b=Disagree | 8.3 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | e=Strongly Agree | 10.0 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | b=Neutral | 28.3 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | g=Neutral | 36.7 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | b=Agree | 18.3 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | e=Not Applicable | 1.7 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | b=Strongly Agree | 16.7 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | h=Disagree | 0 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | b=Not Applicable | 6.7 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | e=Missing | 11.7 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | b=Missing | 11.7 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | g=Agree | 21.7 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | c=Strongly Disagree | 0 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | f=Strongly Disagree | 1.7 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | c=Disagree | 0 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | h=Strongly Agree | 25.0 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | c=Neutral | 53.3 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | f=Disagree | 5.0 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | c=Agree | 18.3 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | g=Strongly Agree | 15.0 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | c=Strongly Agree | 15.0 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | f=Neutral | 46.7 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | c=Not Applicable | 1.7 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | h=Neutral | 15.0 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | c=Missing | 11.7 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | f=Agree | 20.0 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | d=Strongly Disagree | 20.0 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | g=Not Applicable | 1.7 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | d=Disagree | 3.3 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | f=Strongly Agree | 8.3 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | d=Neutral | 30.0 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | h=Missing | 11.7 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | d=Agree | 18.3 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | f=Not Applicable | 6.7 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | d=Strongly Agree | 15.0 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | g=Missing | 11.7 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | d=Not Applicable | 1.7 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | f=Missing | 11.7 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area | d=Missing | 11.7 percentage of HCPs |
Secondary
Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room
HCPs who administered treatment responded to Question 2: If all IV are switched to SC, please indicate how strongly you agree/disagree with each of following statements: a= Participants will be moved outside of infusion unit to receive SC injections (physician consultation room); b=Atezolizumab SC route will allow more flexible treatment scheduling; c=More participants will be treated in infusion unit; d=Waiting list for any IV treatment at infusion unit will be reduced; e=Staff resources will be re distributed to other departments of the hospital (less staffing required within infusion unit); f=There will still be sufficient interaction time between HCPs & participants (for participant education); g=Staff will spend more time for further professional education/development; h=Staff will dedicate more time to attending to administrative tasks for participants; i=Participants will spend less time in care unit; j=Administration by atezolizumab SC injection is preferred by participants.
Time frame: Cycle 6 Day 1 (cycle length=21 days)
Population: Overall number analyzed included HCPs who completed Question 2 of the survey at treatment Cycle 6. Percentages have been rounded off.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | e=Missing | 13.8 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | c=Strongly Disagree | 5.2 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | f=Strongly Disagree | 0 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | b=Strongly Disagree | 5.3 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | f=Disagree | 17.2 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | c=Disagree | 15.5 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | f=Neutral | 17.2 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | a=Strongly Disagree | 13.8 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | f=Agree | 22.4 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | c=Neutral | 12.1 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | f=Strongly Agree | 29.3 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | b=Disagree | 19.0 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | f=Not Applicable | 0 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | c=Agree | 25.9 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | f=Missing | 13.8 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | a=Agree | 27.6 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | g=Strongly Disagree | 6.9 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | c=Strongly Agree | 27.6 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | g=Disagree | 12.1 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | b=Neutral | 10.3 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | g=Neutral | 27.6 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | c=Not Applicable | 0 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | g=Agree | 13.8 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | e=Strongly Disagree | 13.8 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | g=Strongly Agree | 25.9 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | c=Missing | 13.8 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | g=Not Applicable | 0 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | a=Strongly Agree | 17.2 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | g=Missing | 13.8 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | d=Strongly Disagree | 6.9 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | h=Strongly Disagree | 6.9 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | e=Disagree | 8.6 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | h=Disagree | 17.2 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | d=Disagree | 5.2 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | h=Neutral | 15.5 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | a=Disagree | 15.5 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | h=Agree | 24.1 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | d=Neutral | 25.9 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | h=Strongly Agree | 20.7 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | b=Agree | 22.4 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | h=Not Applicable | 1.7 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | d=Agree | 19.0 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | h=Missing | 13.8 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | a=Not Applicable | 10.3 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | i=Strongly Disagree | 1.7 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | d=Strongly Agree | 27.6 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | i=Disagree | 5.2 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | b=Strongly Agree | 27.6 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | i=Neutral | 8.6 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | d=Not Applicable | 1.7 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | i=Agree | 37.9 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | j=Neutral | 20.7 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | i=Strongly Agree | 32.8 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | j=Agree | 31.0 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | d=Missing | 13.8 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | i=Not Applicable | 0 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | e=Neutral | 27.6 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | i=Missing | 13.8 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | b=Not Applicable | 1.7 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | j=Strongly Disagree | 1.7 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | e=Agree | 10.3 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | j=Disagree | 0 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | a=Missing | 13.8 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | e=Strongly Agree | 19.0 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | j=Strongly Agree | 31.0 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | b=Missing | 13.8 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | j=Not Applicable | 1.7 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | e=Not Applicable | 6.9 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | j=Missing | 13.8 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | a=Neutral | 1.7 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | j=Missing | 19.7 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | b=Neutral | 21.3 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | a=Strongly Disagree | 11.5 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | a=Disagree | 23.0 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | a=Neutral | 6.6 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | a=Agree | 23.0 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | a=Strongly Agree | 14.8 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | a=Not Applicable | 1.6 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | a=Missing | 19.7 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | b=Strongly Disagree | 1.6 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | b=Disagree | 14.8 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | d=Missing | 19.7 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | e=Strongly Disagree | 11.5 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | e=Disagree | 14.8 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | b=Agree | 21.3 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | b=Strongly Agree | 21.3 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | b=Not Applicable | 0 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | b=Missing | 19.7 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | c=Strongly Disagree | 0 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | c=Disagree | 16.4 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | c=Neutral | 23.0 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | c=Agree | 26.2 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | c=Strongly Agree | 14.8 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | c=Not Applicable | 0 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | c=Missing | 19.7 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | d=Strongly Disagree | 1.6 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | d=Disagree | 6.6 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | d=Neutral | 31.1 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | d=Agree | 23.0 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | d=Strongly Agree | 18.0 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | d=Not Applicable | 0 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | e=Neutral | 26.2 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | e=Agree | 11.5 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | e=Strongly Agree | 13.1 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | e=Not Applicable | 3.3 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | e=Missing | 19.7 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | f=Strongly Disagree | 0 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | f=Disagree | 11.5 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | f=Neutral | 32.8 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | f=Agree | 16.4 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | f=Strongly Agree | 19.7 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | f=Not Applicable | 0 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | f=Missing | 19.7 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | g=Strongly Disagree | 1.6 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | g=Disagree | 11.5 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | g=Neutral | 27.9 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | g=Agree | 24.6 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | g=Strongly Agree | 14.8 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | g=Not Applicable | 0 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | g=Missing | 19.7 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | h=Strongly Disagree | 0 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | h=Disagree | 24.6 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | h=Neutral | 13.1 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | h=Agree | 29.5 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | h=Strongly Agree | 13.1 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | h=Not Applicable | 0 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | h=Missing | 19.7 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | i=Strongly Disagree | 1.6 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | i=Disagree | 4.9 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | i=Neutral | 14.8 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | j=Neutral | 21.3 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | i=Strongly Agree | 31.1 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | i=Not Applicable | 0 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | i=Missing | 19.7 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | j=Strongly Disagree | 1.6 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | j=Disagree | 3.3 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | j=Agree | 27.9 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | j=Strongly Agree | 26.2 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | j=Not Applicable | 0 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room | i=Agree | 27.9 percentage of HCPs |
Secondary
Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room
HCPs who administered study treatment responded at Cycle 6 of the Treatment Crossover Period to the following HCPQ-treatment room Questions 3 to 7: Looking back over the atezolizumab treatment sessions, please indicate based on your opinion which administration method: Question 3. Which method was most convenient for the participant? Question 4. Which method was best for optimizing participant care in your center? Question 5. Which method took the least time from start to finish of administration? Question 6. Which method required the least resource use for administration? Question 7. Which method was preferred by participants? The five available response options were: Atezolizumab SC, Atezolizumab IV, No Difference, Unsure and Missing. Percentages have been rounded off.
Time frame: Cycle 6 Day 1 (cycle length=21 days)
Population: Overall number analyzed included HCPs who completed Questions 3 to 7 of the survey at treatment Cycle 6.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Q6=Atezolizumab IV | 3.4 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Q6=No Difference | 19.0 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Q6=Unsure | 0 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Q6=Missing | 13.8 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Q7=Atezolizumab SC | 63.8 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Q7=Atezolizumab IV | 10.3 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Q7=No Difference | 3.4 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Q7=Unsure | 8.6 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Q7=Missing | 13.8 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Q3=Atezolizumab SC | 72.4 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Q3=Atezolizumab IV | 5.2 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Q3=No Difference | 6.9 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Q3=Unsure | 1.7 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Q3= Missing | 13.8 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Q4=Atezolizumab SC | 55.2 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Q4=Atezolizumab IV | 6.9 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Q4=No Difference | 20.7 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Q4=Unsure | 3.4 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Q4=Missing | 13.8 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Q5=Atezolizumab SC | 67.2 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Q5=Atezolizumab IV | 0 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Q5=No Difference | 17.2 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Q5=Unsure | 0 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Q5=Missing | 15.5 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Q6=Atezolizumab SC | 63.8 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Q5=Atezolizumab SC | 52.5 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Q3= Missing | 14.4 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Q6=No Difference | 31.1 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Q6=Atezolizumab SC | 50.8 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Q6=Unsure | 0 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Q4=Atezolizumab SC | 39.3 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Q6=Missing | 16.4 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Q5=Atezolizumab IV | 3.3 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Q7=Atezolizumab SC | 52.5 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Q4=Atezolizumab IV | 1.5 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Q7=Atezolizumab IV | 14.8 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Q5=Missing | 16.4 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Q7=No Difference | 1.6 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Q4=No Difference | 31.1 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Q7=Unsure | 14.8 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Q5=No Difference | 27.9 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Q7=Missing | 16.4 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Q4=Unsure | 1.6 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Q3=Atezolizumab SC | 63.9 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Q6=Atezolizumab IV | 1.6 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Q3=Atezolizumab IV | 10.1 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Q4=Missing | 16.4 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Q3=No Difference | 8.4 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Q5=Unsure | 0 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room | Q3=Unsure | 3.3 percentage of HCPs |
Secondary
Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 8 of HCPQ - Treatment Room
HCPs who administered study treatment responded at Cycle 6 of the treatment Cross-over Period to the following HCPQ-treatment room Question 8: How frequently would you offer or recommend atezolizumab SC administration to your participants in the future? The four available response options were Always, Sometimes, Never and Missing. Percentages have been rounded off.
Time frame: Cycle 6 Day 1 (cycle length= 21 days)
Population: Overall number analyzed included HCPs who completed Question 8 of the survey at treatment Cycle 6.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 8 of HCPQ - Treatment Room | Question 8=Always | 41.4 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 8 of HCPQ - Treatment Room | Question 8=Sometimes | 34.5 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 8 of HCPQ - Treatment Room | Question 8=Never | 10.3 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 8 of HCPQ - Treatment Room | Question 8=Missing | 13.8 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 8 of HCPQ - Treatment Room | Question 8=Missing | 16.4 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 8 of HCPQ - Treatment Room | Question 8=Always | 31.1 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 8 of HCPQ - Treatment Room | Question 8=Never | 14.8 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 8 of HCPQ - Treatment Room | Question 8=Sometimes | 37.7 percentage of HCPs |
Secondary
Percentage of HCPs by Their Response to Perception of Time/Resource Use for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 and 4 of HCPQ - Drug Preparation Area
HCPs who prepared study treatment within the pharmacy/drug preparation area responded at to the following HCPQ-Drug Preparation Area Questions 3 and 4, at Cycle 6 of the Treatment Crossover Period for every participant: Looking back over the Atezolizumab treatment sessions, please indicate based on your opinion which administration method: Question 3. Was quickest from start to end of preparation to finish of administration (excluding observation period)?; Question 4. Required less resource use for preparation and administration, for example nursing time, facility costs, equipment etc? The four available response options were: Atezolizumab IV, Atezolizumab SC, No Difference, and Missing. Percentages have been rounded off.
Time frame: Cycle 6 Day 1 (cycle length= 21 days)
Population: Overall number analyzed included HCPs who completed Questions 3 and 4 of the survey at treatment Cycle 6.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Time/Resource Use for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 and 4 of HCPQ - Drug Preparation Area | Question 3=Atezolizumab SC | 71.9 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Time/Resource Use for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 and 4 of HCPQ - Drug Preparation Area | Question 3=Atezolizumab IV | 0 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Time/Resource Use for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 and 4 of HCPQ - Drug Preparation Area | Question 3=No Difference | 17.5 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Time/Resource Use for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 and 4 of HCPQ - Drug Preparation Area | Question 3=Missing | 10.5 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Time/Resource Use for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 and 4 of HCPQ - Drug Preparation Area | Question 4=Atezolizumab SC | 64.9 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Time/Resource Use for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 and 4 of HCPQ - Drug Preparation Area | Question 4=Atezolizumab IV | 3.5 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Time/Resource Use for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 and 4 of HCPQ - Drug Preparation Area | Question 4=No Difference | 21.1 percentage of HCPs |
| Crossover Atezolizumab IV/SC | Percentage of HCPs by Their Response to Perception of Time/Resource Use for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 and 4 of HCPQ - Drug Preparation Area | Question 4=Missing | 10.5 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Time/Resource Use for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 and 4 of HCPQ - Drug Preparation Area | Question 4=Missing | 20.0 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Time/Resource Use for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 and 4 of HCPQ - Drug Preparation Area | Question 3=Atezolizumab SC | 58.3 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Time/Resource Use for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 and 4 of HCPQ - Drug Preparation Area | Question 4=Atezolizumab SC | 60.0 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Time/Resource Use for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 and 4 of HCPQ - Drug Preparation Area | Question 3=Atezolizumab IV | 0 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Time/Resource Use for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 and 4 of HCPQ - Drug Preparation Area | Question 4=No Difference | 20.0 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Time/Resource Use for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 and 4 of HCPQ - Drug Preparation Area | Question 3=No Difference | 21.7 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Time/Resource Use for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 and 4 of HCPQ - Drug Preparation Area | Question 4=Atezolizumab IV | 0 percentage of HCPs |
| Crossover Atezolizumab SC/IV | Percentage of HCPs by Their Response to Perception of Time/Resource Use for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 and 4 of HCPQ - Drug Preparation Area | Question 3=Missing | 20.0 percentage of HCPs |
Secondary
Percentage of Participants Who Select Atezolizumab SC for Treatment Continuation Period
At Cycle 6, Day 1, participants were expected to select the route of study treatment administration (SC or IV) they would like to receive during the Treatment Continuation Period (starting at Cycle 7). Percentage of participants who chose SC administration have been reported here. Percentages have been rounded off.
Time frame: Cycle 6 Day 1 (Cycle length=21 days)
Population: FAS included all randomized participants. Overall number analyzed is the number of participants with data available for analysis.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Crossover Atezolizumab IV/SC | Percentage of Participants Who Select Atezolizumab SC for Treatment Continuation Period | 78.2 percentage of participants |
| Crossover Atezolizumab SC/IV | Percentage of Participants Who Select Atezolizumab SC for Treatment Continuation Period | 76.7 percentage of participants |
Secondary
Percentage of Participants With Adverse Events (AEs)
An AE is untoward medical occurrence in a participant administered a pharmaceutical product and regardless of causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom/disease temporally associated with use of investigational product, whether or not considered related to the investigational product. Percentages have been rounded off.
Time frame: Up to 90 days after the final dose of study drug (Up to 2.4 years)
Population: Safety evaluable population included all participants who received at least one dose of study treatment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Crossover Atezolizumab IV/SC | Percentage of Participants With Adverse Events (AEs) | 59.4 percentage of participants |
| Crossover Atezolizumab SC/IV | Percentage of Participants With Adverse Events (AEs) | 47.7 percentage of participants |
| All Participants | Percentage of Participants With Adverse Events (AEs) | 76.9 percentage of participants |
| Continuation Atezolizumab SC | Percentage of Participants With Adverse Events (AEs) | 67.4 percentage of participants |
Secondary
Percentage of Participants With AEs During Treatment Cross-over Period
An AE is untoward medical occurrence in participant administered a pharmaceutical product and regardless of causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom/disease temporally associated with use of investigational product, whether or not considered related to investigational product. The safety of switching from atezolizumab SC to atezolizumab IV and from atezolizumab IV to atezolizumab SC is being assessed in this outcome measure. Percentages have been rounded off.
Time frame: From Cycle 1 Day 1 up to Cycle 3 Day 21; From Cycle 4 Day 1 up to Cycle 6 Day 21 (cycle length=21 days)
Population: Safety evaluable population included all participants who received at least one dose of study treatment. In this analysis, participants were grouped by study arm and treatment period during the Crossover Period.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Crossover Atezolizumab IV/SC | Percentage of Participants With AEs During Treatment Cross-over Period | 62.9 percentage of participants |
| Crossover Atezolizumab SC/IV | Percentage of Participants With AEs During Treatment Cross-over Period | 39.1 percentage of participants |
| All Participants | Percentage of Participants With AEs During Treatment Cross-over Period | 54.7 percentage of participants |
| Continuation Atezolizumab SC | Percentage of Participants With AEs During Treatment Cross-over Period | 53.5 percentage of participants |
Secondary
Percentage of Participants With Ongoing Clinical Benefit
Participants were assessed for clinical benefit at every tumour assessment visit, which was conducted as per the local standard of care. Percentages have been rounded off.
Time frame: Up to Cycle 16 (cycle length= 21 days)
Population: FAS included all randomized participants. Ongoing clinical benefit at Cycle 16 was summarized for overall participants, as due to switches in mode of administration up to Cycle 16, it would be impossible to isolate the effect of the randomization arms. Hence, per-arm data can't be presented.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Crossover Atezolizumab IV/SC | Percentage of Participants With Ongoing Clinical Benefit | 44.7 percentage of participants |